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Resumo 
O diabetes tipo 2 (DT2) é uma doença poligénica com prevalência mundial, que 
depende de fatores de risco genéticos, epigenéticos e ambientais. Estudos de 
associação genómica (GWAS) mostraram que polimorfismos de nucleótido único 
(SNPs) não-codificantes estão associados à suscetibilidade a DT2. Alguns desses 
SNPs não só se sobrepõem a regiões caracterizadas por marcas epigenéticas de 
elementos cis-reguladores (CREs), como também residem dentro de áreas regulatórias 
de genes pancreáticos, como é evidenciado por dados da técnica de Hi-C realizada em 
ilhotas pancreáticas humanas. Um desses SNPs situa-se no locus do gene “Pancreatic 
and Duodenal Homeobox 1” (PDX1). 
O fator de transcrição PDX1 desempenha um papel crucial no desenvolvimento 
inicial do pâncreas, na diferenciação de linhagens endócrinas e na função das células 
beta. Mutações heterozigóticas estão associadas a diabetes de uma forma monogênica 
de diabetes de manifestação precoce (MODY4), enquanto níveis reduzidos da 
expressão de PDX1 são frequentemente observados em DT2. 
Neste trabalho, pretendemos introduzir o locus PDX1 humano no genoma do peixe-
zebra, fornecendo, portanto, um modelo animal humanizado para realizar estudos in 
vivo. Concluímos que um cromossoma artificial bacteriano (do inglês, BAC) de 200 kilo 
bases contendo o gene PDX1 representa seu contexto regulatório transcricional. O 
PDX1-BAC foi manipulado de forma a inserir locais de reconhecimento da transposase 
Tol2 para aumentar a eficiência da transgénese e um repórter GFP para gerar uma 
proteína PDX1 de fusão para acompanhar sua expressão in vivo. O elemento 
transponível PDX1-BAC foi injetado no peixe-zebra no estadio de uma célula para gerar 
linhas transgénicas, que podem ser facilmente manipuladas pela edição do genoma do 
CRISPR-Cas9, de forma a caracterizar in vivo o papel de polimorfismos conhecidos e 
novos CREs identificados. Além disso, ao explorar o locus PDX1 no que diz respeito a 
marcas epigenéticas, acessibilidade e conformação da cromatina, selecionamos seis 
putativos CREs de PDX1. Além disso, validamos parte dessas sequências isoladas 
humanas para a função intensificadora ou isoladora in vivo em peixe-zebra. 
Esta abordagem fornecerá um poderoso modelo in vivo para investigar elementos 
não codificantes que regulam os níveis de expressão de PDX1, elucidando os 
mecanismos moleculares que contribuem para a suscetibilidade de DT2. A avaliação do 
impacto in vivo de mutações humanas no desenvolvimento de características 
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associadas à diabetes pode refinar estratégias de diagnóstico de DT2 e intervenções 
terapêuticas. 
 
Palavras-chave: Diabetes Tipo 2 (DT2), Pancreatic and Duodenal Homeobox 1 
(PDX1), Genome-Wide Association Studies (GWAS), polimorfismos de nucleótido único 
(SNPs), regulação em cis, intensificador, isolador, contexto regulatório, Danio rerio, 
transgénese, Tol2. 
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Abstract 
Type-2 Diabetes (T2D) is a polygenic disease with a worldwide prevalence, which 
depends on genetic, epigenetic and environmental risk factors. Genome-Wide 
Association Studies (GWAS) have shown that non-coding single nucleotide 
polymorphisms (SNPs) are associated to T2D susceptibility. Some of these SNPs not 
only overlap with regions characterised by epigenetic marks of cis-regulatory elements 
(CREs), but also reside within the regulatory landscapes of pancreatic genes, as seen 
by Hi-C data for human pancreatic islets. One of such SNPs lays in the locus of the 
Pancreatic and Duodenal Homeobox 1 (PDX1) gene. 
The transcription factor PDX1 plays a crucial role in early pancreas development, 
differentiation of endocrine lineages and beta cell function. Heterozygous mutations are 
associated with Maturity-Onset Diabetes of the Young (MODY4), an early-onset 
monogenic form of diabetes, while reduced PDX1 expression levels are often observed 
in T2D. 
In this work we aim to introduce the human PDX1 locus into the zebrafish 
genome, therefore providing a humanized animal model to perform in vivo studies. We 
reasoned that a Bacterial Artificial Chromosome (BAC) spanning 200 kilobases 
containing the PDX1 gene represents its transcriptional regulatory landscape. The 
PDX1-BAC was engineered by inserting Tol2 transposase recognition sites to enhance 
transgenesis efficiency and a GFP reporter to generate a fusion PDX1 protein to trace 
its expression in vivo. The PDX1-BAC transposable element was injected in one-cell 
stage zebrafish to generate transgenic lines, which can be easily manipulated by 
CRISPR-Cas9 genome editing to characterise in vivo the role of known polymorphisms 
and novel identified CREs. Additionally, by screening the PDX1 locus for epigenetic 
marks, chromatin accessibility and conformation, we selected six putative PDX1 CREs. 
We further validated part of these human isolated sequences for enhancer or insulator 
function in vivo in zebrafish. 
This approach will provide a powerful in vivo model to investigate non-coding 
elements regulating PDX1 expression levels, elucidating the molecular mechanisms 
contributing to T2D susceptibility. Assessing the impact of human mutations for the 
development of diabetes-associated traits in vivo could refine T2D diagnostic strategies 
and therapeutic interventions. 
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Introduction 
1) Chromatin structure and Epigenetics 
Epigenetics refers to DNA modifications involved in modulation of gene function, 
through changes in chromatin structure and accessibility without alteration at DNA 
sequence level [1]. In eukaryotes, the genetic information required for normal cell 
function is contained within the nucleus. Double-stranded deoxyribonucleic acid (DNA) 
is packed together with proteins, histones, forming DNA-protein complexes called 
nucleosomes. Nucleosomes are the core units of chromatin, which comprise 146 bp of 
a DNA sequence wrapped around an octamer of histone proteins [2].  
Chromatin organization is fundamental for cell function, meaning that specific 
chromatin three-dimensional (3D) structure is associated with cell division and gene 
expression. On one hand, throughout cell division, the chromatin is arranged in its 
highest compact form. Several nucleosomes assemble together in loops and establish 
the units of chromatin, forming chromatin fibers. Chromatin packaging allows to arrange 
the genetic material in a compact way inside the cell nucleus [2]. On the other hand, 
during interphase, specific genomic regions are characterised by layers of chromatin 
accessibility, ensuring proper gene expression. Chromatin accessibility is related to the 
availability of DNA sequences to the transcriptional machinery [3].  
Chromatin comprehends regions that are highly condensed and coiled – termed 
heterochromatin –, and regions that are more accessible – euchromatin. The constitutive 
heterochromatin is composed by structural chromosomic regions that retain their original 
condensed state during the interphase of the cell cycle – these include the centromere 
and telomeres. The other type of heterochromatin is called facultative, accordingly to its 
adjustable state of condensation, that is mainly dependent on histone modifications and 
differs between cell types [2]. In euchromatin, as the structure is more relaxed and 
available to transcription factors (TFs), these regions of chromatin are mainly associated 
with gene expression and transcriptional regulation [4]. 
The frequency of nucleosomes is enriched in facultative and constitutive 
heterochromatin, while it is decreased in euchromatin holding DNA regulatory 
sequences. The enrichment on nucleosomes contributes to determine chromatin 
accessibility, and therefore to gene expression regulation [5]. The modulation of 
nucleosome affinity to the chromatin depends on the histones and their posttranslational 
modifications, constituting one of the key epigenetic mechanisms of transcriptional 
regulation, often referred as “histones code”. Histones are proteins that can undergo 
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covalent modifications upon translation, through methylation, phosphorylation, 
acetylation, ubiquitylation and sumoylation processes. Facultative heterochromatin and 
inactive gene promoters are characterised by the presence of histone H3 lysine 27 
trimethylation (H3K27me3) mark that leads to gene repression and silencing. 
Additionally, constitutive heterochromatin, is predominantly marked by other repressive 
modifications – H3K9 di- and trimethylation (H3K9me2 and H3K9me3). Specific histone 
modifications are used in the prediction of regulatory elements, such as enhancers. 
Putative enhancers are defined by enrichment in H3K27 acetylation (H3K27ac) and 
H3K4 monomethylation (H3K4me1) epigenetic marks. Particularly, while primed and 
active enhancers are both characterised by H3K4me1 enrichment, H3K27ac mark allows 
to distinguish active enhancers [6-8].  
The transcription factors (TFs) required for proper gene transcription are in 
continuous and dynamic competition with histones, to modulate chromatin accessibility 
[4]. Finally, DNA methylation is also a crucial mechanism for proper regulation of gene 
expression, which is predominant in palindromic CpG dinucleotides in mammalian 
genomes (CpG islands). Active gene promoters are typically unmethylated, correlated 
with the requirement for this type of sequences to be accessible to TFs. Opposingly, 
heterochromatin and several inactive gene promoters are enriched in CpG methylation 
[4]. 
 
a) Transcriptional regulation and cis-regulatory elements  
The genome contains genes that are transcribed to copies of ribonucleic acid (RNA) 
molecules, which are then translated into proteins – functional macromolecules that act 
on different cellular processes [2]. Transcription is thus one of the first steps on which 
different factors can act and regulate gene expression.  
In eukaryotes, gene transcription starts in the cell nucleus upon binding of RNA 
Polymerase II (Pol II) to the gene promoter region – canonically defined by a conserved 
sequence that composes the TATA box. The functional recruitment of Pol II is ensured 
by the stepwise assembly of several co-factors, in turn stabilized by binding of TFs and 
chromatin modulators [6]. When the transcription initiation complex is formed, Pol II starts 
synthesizing a molecule of messenger RNA (mRNA), by adding nucleotides 
complementary to the DNA template. The newly synthesized mRNA is then transferred 
to the cell cytoplasm, where it is translated into an amino acidic sequence establishing 
functional proteins [2, 9]. 
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The human genome is constituted not only by coding DNA used as template for 
synthesis of proteins, which represent 2% of the genome, but also by non-coding DNA. 
This non-coding DNA, previously referred as “junk DNA”, composes 98% of the entire 
human genome. More recently it has been shown that the non-coding DNA comprises 
several regulatory sequences required for transcriptional regulation [9]. Moreover, 
almost half of the non-coding human DNA is transcribed to several types of RNA 
molecules, such as transfer and ribosomal RNAs (tRNAs and rRNAs, respectively) that 
are part of the machinery involved in regulation of gene expression [2, 9]. 
 
Although the mechanism of Pol II binding to the promoter region of a gene is 
fundamental to initiate transcription, the regulatory mechanisms that act at the 
transcriptional level are even more complex and dependent on several factors. The 
complexity associated to specific gene expression patterns, both in space and time, is 
dependent on the congregated action of all the regulatory elements that compose a 
gene’s regulatory landscape [10]. The regulatory landscape of a human gene usually 
includes several cis-regulatory elements (CREs). CREs are non-coding DNA sequences 
characterised by transcription factor-binding sites (TFBS), which are able to physically 
interact with gene promoters by chromatin loops, regulating gene expression in a specific 
manner. These elements can be classified in two major classes, according to their 
position regarding the site where gene transcription is initiated. The proximal CREs 
consist mostly on gene promoters, while the distal CREs include distal regulatory 
sequences, such as enhancers and insulators [9].  
 
(1) Enhancers 
Enhancers are described as genomic regions that are able to interact with gene 
promoters, increasing gene transcription [11]. The first reference to enhancers emerged 
from molecular cloning studies on which DNA sequences from the SV40 virus were 
demonstrated to increase the transcription levels of the rabbit haemoglobin β-globin 
gene cloned in the same vector [12]. Enhancers are regulatory elements acting in cis, 
through mechanisms that are independent on the orientation of its sequence. Moreover, 
the function of enhancers also seems to be independent of the distance between them 
and the promoter of their target genes, as it has been illustrated in the case of the 
vertebrate ZRS enhancer controlling the Sonic hedgehog (Shh) gene located one 
megabase (Mb) away [13].  
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Enhancers are typically mapped in intergenic sequences, but they can also be 
located in introns or exons of genes, either their own target gene or genes of the 
neighbourhood. These regulatory elements respond to intrinsic and external stimuli [6, 
9]. The function of an enhancer depends on the binding of specific TFs, capable to recruit 
additional transcriptional factors and chromatin remodelers, which enable the physical 
interaction between enhancer and promoter. For instance, Mediator constitutes an 
evolutionary conserved protein complex recruited by TFs bound to enhancers, that is 
able to directly interact with Pol II and other transcriptional co-factors, being a 
transcriptional key-regulator [14]. The interaction between proteins bound to the 
enhancer and the ones bound to the promoter seems to dictate the activation of 
transcription of the target gene [11]. Thus, enhancers are regulatory elements that define 
precise spaciotemporal gene expression, particularly crucial in vertebrate development 
[9].  
 
(2) Insulators 
Insulators are CREs characterised by an ability to protect genes from transcriptional 
activation from enhancers belonging to other regulatory landscapes, also known as 
“enhancer blocking effect” [15]. This way, insulators might define genomic regions in 
which sequences are more likely to communicate with each other, while insulated from 
other adjacent sequences, functioning as regulatory boundaries [16]. Insulators 
characterised as boundary elements usually harbour binding sites of insulator proteins. 
In vertebrates, the key protein binding to insulator sequences is the CCCTC-binding 
(CTCF) protein [11]. CTCF is a DNA-binding protein containing a domain formed by 11 
central zinc finger proteins. Moreover, insulators bound by CTCF proteins are highly 
accessible yet they are sequences contained within regions characterised by a high 
occupancy of nucleosomes [15, 16]. The DNA sequence at the 5′ end of the chicken β-
globin locus (5’HS4), is a 1,2-kb DNA sequence upstream the β-globin locus and 
constitutes one of the first sequences described as an insulator [17]. 
 
Data from chromatin conformation assays demonstrated that the genome is 
organized in topological associating domains (TADs) [11]. TADs are defined as genomic 
regions characterised by long-range interactions between promoters and distal 
enhancers [18]. This type of genomic arrangement is characterised by preferential 
interactions between loci of the same TAD, defined by insulators that block interactions 
from loci that locates outside that TAD. Thus, the 3D organization of the genome 
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modulates gene expression [10, 11]. TADs boundaries are defined by the presence of 
CTCF and cohesin binding regions. CTCF complexes bind to specific sites, recruiting 
cohesin. The classical role of cohesin is associated to sister chromatids cohesion during 
mitosis and DNA repair by recombination [19]. More recently, cohesin has been 
proposed to act downstream the CTCF complex on chromatin modulation network, 
allowing chromatin to fold into loop structures [4, 20]. Different models have been 
proposed regarding the mechanisms of TAD formation, being the loop extrusion model 
the common consensus for vertebrates (Figure 1) [21]. In this conformational model, the 
dynamic binding of TFs results in physical proximity between regulatory genomic 
regions, conformations held by the cohesin complexes. Cohesin is recruited to the DNA 
by CTCF, beginning an extrusion DNA loop that extends until cohesin detects an 
adjacent occupied CTCF-binding site [20]. Meanwhile, Polymerase II binds to gene 
promoters and transcription can be activated by proximal enhancers [11]. This model 
adjusts well in the light of a mechanism of promoter competition, where the proximity 
between promoter and enhancer acts as an advantage to mediate interactions [11, 22]. 
Regarding high order structure, the topological organization defined by TADs helps to 
explain the favouring of some long-range interactions. The presence of TADs boundaries 
defines regions where genes and CREs contained within seem to preferentially interact 
with each other (Figure 1), therefore establishing genomic regulatory regions [22]. 
Enhancers appear to play a limited role regarding specificity for their target promoters, 
whereas the establishment of TADs acts a determinant factor in the formation of specific 
interactions of those enhancers with target promoters [19]. The dynamic binding of TFs 
to enhancers, together with the distribution of CREs in TADs are suggested to regulate 
specific promoter-enhancer interactions required during development and in different 
tissues [21, 22]. 
 
b) Characterization of the chromatin  
Several techniques have been developed to study different properties of the 
chromatin, from analysis of specific loci to the “omics” included in genome wide studies. 
Next-generation sequencing (NGS) enabling to process and organize high-throughput 
data from genomic, transcriptomic and epigenomic techniques underwent a fast 
development during the early 2000’s. Bioinformatics analysis of genome-wide data 
greatly contributed to understand the molecular basis of complex human diseases [23]. 
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• DNA accessibility 
In order to enable the binding of TFs to regulatory sequences, those sequences are 
required to be accessible, meaning that they usually need to be contained within 
nucleosome-free regions [5]. Several techniques have been developed to identify 
accessible or open regions of chromatin. Chromatin digestion by micrococcal nuclease 
(MNase) was one of the first technique employed to investigate chromatin accessibility. 
This nuclease is able to cut double-stranded DNA linking sequences between 
nucleosomes, providing information on nucleosome location [24]. Higher resolution can 
be obtained by other technique that allows identifying accessible chromatin regions – 
DNase I-Seq. This allows to identify genomic regions sensible to the activity of the 
hypersensible endonuclease DNase I, followed by sequencing of the digested fragments 
[25]. An alternative technique used to this end is the Formaldehyde-Assisted Isolation of 
Regulatory Elements coupled to high-throughput sequencing (FAIRE-Seq). FAIRE 
enables to identify open chromatin regions, through the isolation of nucleosome-free 
DNA from the occupied DNA and assessment of actively transcribed sequences [26]. 
The mapping of accessible chromatin regions through the techniques described 
above requires high input of DNA samples, which is not always possible. A technique 
requiring lower amount of chromatin is the assay for Transposase Accessible Chromatin, 
followed by high-throughput sequencing (ATAC-Seq). This type of assay makes use of 
a highly active transposase (Tn5) to evaluate the accessibility of certain genomic regions. 
The transposase binds to accessible sites and fragments DNA, then enabling the 
insertion of sequencing adapters [18]. Sequencing results are then analysed to create 
maps of open chromatin, reflecting nucleosome position and accessibility [27]. 
Figure 1. Topologically associating domains (TADs). TADs define genomic regions where 
promoters and enhancers interact. The binding of specific TFs explains helps to explain the variety of 
interactions that could be detected within a TAD. Adapted from Hnisz, D et al. 2016. 
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• TF binding  
The activity of transcriptional regulatory sequences is also in part modulated by 
interactions between DNA and DNA-binding proteins [5]. In order to identify in vivo 
binding of a given TF to a DNA sequence, Chromatin Immunoprecipitation coupled to 
high-throughput sequencing (ChIP-Seq) is the prime technique. In this assay, chromatin 
is sonicated and immunoprecipitated with specific antibodies, followed by massive 
parallel sequencing. ChIP can be used to detect the biding of TFs and also histone 
modifications; this technique requires previous information regarding potential 
transcription factors that might bind to the regulatory sequences in test, so that specific 
antibodies can be selected [28]. 
• DNA conformation 
Transcriptional cis-regulation by long-range interactions, depends greatly on the 3D 
structure of the chromatin [29]. This structure can be evaluated by Chromatin 
Conformation Capture (3C) and associated technologies. Reported for the first time in 
2002, the 3C technique relies on formaldehyde crosslinking of chromatin, followed by 
digestion with restriction enzymes and intramolecular ligation of cross-linked fragments 
[30]. The ligated fragments are hybrid DNA molecules, which reflects the frequency of 
the in vivo interactions mediated by protein complexes. Development of this technique 
allowed using the ligated DNA as template in quantitative PCR reactions to identify the 
physical distance between desired loci in the 3D structure of the chromatin in the cell’s 
nucleus. This way, 3C constitutes a quantitative technique to detect the frequency if 
interactions among 2 loci [31].  
Based on 3C, several technologies have been developed and coupled with Next 
Generation Sequencing. Most of these technologies present common initial steps, 
comprising crosslinking, digestion and ligation of digested chromatin fragments [29]. The 
Circularized Chromosome Conformation Capture (4C) technique offers several 
advantages in comparison to 3C. The establishment of circular fragments enables to 
capture conformations that reflect genome-wide interactions between unknown DNA 
sequences and the viewpoint [32]. Other important breakthrough in chromatin 
conformation analysis was the establishment of the Hi-C protocol. Using an all-to-all 
approach, Hi-C differs allows identifying simultaneously cis- and trans-interactions in an 
unbiased way, that is, without a specific and pre-selected viewpoint [33]. For this reason, 
Hi-C is considered an unbiased genome-wide assay. The Hi-C technique could also be 
applied to more specific purposes, such as the promoter capture Hi-C (pcHi-C). pcHi-C 
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enables to identify interactions between targeted promoters and CREs with high-
confidence, allowing to create high-resolution chromatin interactome maps [18]. 
 
c) The contribution of chromatin organization and cis-regulation to disease 
development 
Complex or multifactorial diseases, such as cancer and diabetes, result from a 
combination of genetic and environmental factors. Moreover, complex diseases are 
defined by genetic traits derived from different loci that characterise disease 
predisposition. Human complex diseases are frequently associated to the dysregulation 
of gene transcription. The concomitant lack of point mutations in the coding sequence of 
given genes highlights the relevance of genetic variants in non-coding sequences to the 
development of those diseases [10, 34]. Indeed, the overlap between non-coding 
polymorphisms associated to disease, identified by genome wide association studies 
(GWAS), and identified regulatory elements, such as enhancers, suggests an impact on 
transcriptional regulation [34-36]. In spite of the corroborated importance of cis-
regulation to the development of human diseases [37, 38], a formal demonstration and 
the mechanisms associated to the impairment of normal cis-regulatory networks remain 
elusive.  
Transcription regulation mechanisms correlate with an increased complexity in gene 
expression patterns, being the source of differential gene expression throughout 
vertebrate development [2]. Consequentially, several diseases arise from the 
dysregulation of regulatory mechanisms that interfere with the complex synchronization 
of cellular functions [6, 10, 11]. Therefore, it is essential to describe human chromatin 
conformation maps in order to study the molecular mechanisms inherent to the 
pathogenesis of those diseases. 
The evolution of chromatin conformation assays, complemented with the functional 
analysis of relevant loci associated to complex diseases, brings new insights into the 
regulatory mechanisms underlying pathogenic pathways. A noteworthy example related 
to the main focus of this thesis – the study of the pancreas – came in 2017, with the 
online release of the Islet Regulome Browser [23]. This tool gathers genomic, 
epigenomic and transcriptomic results from genome-wide studies from human islets, 
predicting the genomic location of CREs active in human islets: in detail, this browser 
integrates data from FAIRE-Seq, ChIP-Seq, mRNA-Seq, ATAC-Seq and pcHi-C; 
moreover, it includes data from human adult pancreatic islets as well as pancreatic 
progenitors cell types [7, 18, 23, 28, 39]. This platform allows the integration of processed 
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data from different sources in a fast and easily way [23]. In summary, the Islet Regulome 
Browser enables the scrutiny of regulatory networks and the selection of loci for 
experimental designs, namely in diabetes research [23]. 
 
 
2) Pancreas 
a) Pancreas organization 
The human pancreas is a glandular organ with important roles on both digestive and 
endocrine systems [40]. Functionally, it can be divided in exocrine and endocrine 
compartments. 
The exocrine pancreas is composed by epithelial acinar cells, responsible for the 
production of digestive enzymes – trypsin, chymotrypsin, amylase and lipase – and 
ductal cells, organized into ducts that converge to the main pancreatic duct. This 
structure enables the secretion of such enzymes to the duodenum [38, 42]. In cases of 
dysfunction of the acinar cells or obstruction of the pancreatic duct, the secretion of 
digestive enzymes can get compromised, as well as the digestive process. This type of 
dysfunctions can lead to the development of pancreatic inflammation and tumorigenesis, 
namely adenocarcinoma [41, 42]. 
 
 
The endocrine pancreas is responsible for the production of several hormones 
involved in glucose homeostasis [43], which are released to the blood vessels [44]. The 
Figure 2. Schematic representation of islets and cell types 
present in human pancreas. Adapted from Efrat, S., & Russ, H. A. (2012). 
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endocrine cells are organised in clusters imbedded in exocrine cells (Figure 2). These 
clusters are called islets of Langerhans and comprise α-, β-, δ-, ε- and γ-cells that 
produce glucagon, insulin, somatostatin, ghrelin and pancreatic polypeptide, respectively 
[45]. Glucose homeostasis is primarily ensured through a correct balance between 
glucagon and insulin. Proper production of these enzymes is regulated by a feedback 
loop to maintain this balance. While insulin decreases blood glucose levels, glucagon 
exerts the opposite effect [2]. Moreover, somatostatin inhibits the production of both 
insulin and glucagon. Impairment of normal endocrine cell function results in abnormal 
levels of pancreatic hormones, and therefore in dysregulation of glucose blood levels – 
a pathogenic phenotype that characterises diabetes mellitus [45]. 
 
b) Vertebrate pancreatic development 
The vertebrate pancreas is derived from the foregut of the embryo, which undergoes 
complex signalling pathways to induce the formation of the ventral and dorsal pancreatic 
buds [45]. Most part of the information gathered about the induction and development of 
the vertebrate pancreas regards genetic studies in mice, which are also the basis of the 
regulatory networks that will be explained hereafter. 
The pancreatic buds are composed by proto-differentiated Multipotent Progenitor 
Cells (MPCs). Right in the first stages of pancreatic development, MPCs express the 
pancreatic and duodenal homeobox 1 (Pdx1) and the pancreas transcription factor 1A 
(Ptf1a). The relevance of Pdx1 and Ptf1a is highlighted by homozygous mutations of 
each gene in mice, which induce pancreatic agenesis [42]. Pdx1 and Ptf1a are 
suggested to be crucial TFs required to induce proper development of the pancreas, with 
Pdx1 even being earlier expressed in the primitive gut [46].  
Other TFs have been reported to act upstream Pdx1 and Ptf1a. The presence of 
binding sites for SRY-Box9 (Sox9) on the promoter of Pdx1, as well as its regulatory 
function regarding the expression of Hepatocyte nuclear factor 1 b (Hnf1b), Hepatocyte 
nuclear factor (Hnf6) and Forkhead box A2 (Foxa2), suggests that Sox9 plays an 
important role in the pancreatic regulatory network. Moreover, later during development 
Sox9 inducts the progression of progenitors towards the exocrine fate [47]. 
The establishment of the pancreatic buds is followed by pancreatic morphogenesis, 
a tightly coordinated process that involves cell polarization and epithelial stratification 
and arrangement into microlumen structures [46]. In rodents, pancreatic organogenesis 
is characterised by two consecutive temporal transitions. The first one comprehends 
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pancreatic induction, budding and fusion, along with the formation and proliferation of a 
pool of MPCs and development of the microlumen. This stage is characterised a first 
wave of endocrine cells formation, during which the first α- and β-cells are produced [43]. 
Upon pancreatic budding, multipotent MPCs located in the “tip” domain of the developing 
pancreas, are characterised by expression of Ptf1a, while cells located in the “trunk” 
domain express homeobox protein NK6 homeobox 1 (Nkx6.1). Nkx6.1+ cells are 
bipotent, as they are committed whether to ductal or endocrine cells [45]. During the 
second transition, the microlumen undergoes a morphogenic remodelling process to 
constitute the luminal network and the second wave of endocrine cell formation, the 
progenitor cells.  
Throughout pancreas development, the balance between levels of the bHLH TF 
neurogenin 3 (Neurog3) and the Notch signalling factors seem to be determinant to cell 
differentiation. During the bud stages, mice pancreatic progenitors transiently express 
Neurog3 for a time period of 12 to 24h. Neurog3 expression undergoes two transient 
periods, correspondent to the two waves of pancreatic organogenesis [48]. The 
expression of this gene is upregulated by Notch signals , as loss-of-function studies in 
mice mutants showed that high levels of Notch induce the expression of Sox9 and, 
consequently, the expression of Neurog3 [49]. Notch is suggested to be a crucial 
orchestrator of pancreas development, being required to the proliferation of MPCs and 
the maintenance of the progenitor state of these cells. Moreover, Notch activity in 
progenitors regulates the patterning of the pancreas in “tip” and “trunk” domains, by 
activating Nkx6.1 expression and repressing Ptf1a [45]. 
Furthermore, the Notch pathway is involved in the determination of cell lineage 
commitment. Neurog3high cells seem to be deviated from the progenitor state, by 
induction of cell cycle exit, and determined to an exocrine fate – in these cells, the high 
levels of Sox9 induce the differentiation of ductal cells, while the maintenance of high 
levels of Ptf1a leads cells towards an acinar fate. On the contrary, low levels of Notch 
induce not only the expression of Sox9, but also the expression of Hes1, that act together 
on the downregulation of Neurog3. Neurog3low cells transiently re-enter cell cycle before 
the second transition, giving rise to unipotent endocrine precursors [49, 50]. Moreover, 
Neurog3 undergoes posttranslational regulation from the Notch signalling pathway, 
through protein destabilization [50]. The congregated action of endocrine-associated 
TFs, along with the downregulation of progenitor-associated markers, is then suggested 
as a determining factor to proper endocrine differentiation and function [43, 48].  
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Additionally, the environmental niches in which the progenitors are contained also 
influence the fate of progenitor cells. For instance, after embryonic day (E) 12,5 of mouse 
development, the epithelial stratification induces the restriction of MPCs to the acinar 
fate and the clustering of endocrine progenitors that will form the islets of Langerhans 
[43, 48]. 
 
• Human pancreatic development 
The human pancreas arises from the ventral and dorsal buds of the embryo foregut, 
which later fuse in order to constitute a unique organ. Human pancreatic development 
presents several common aspects with the murine one [44]. During early embryogenesis, 
transient expression of NEUROG3 is present in humans, as it is in rodents. The crosstalk 
among NEUROG3 and the Notch signalling is also implied in the maintenance of 
pancreatic progenitors and cell differentiation [43]. In contrast, a single wave of endocrine 
cells differentiation occurs and the pancreatic morphology acquired upon cell 
rearrangement also differs [43]. MPCs begin to proliferate already before evagination of 
the pancreatic buds, establishing a pool of progenitors throughout embryogenesis [51]. 
Endocrine or exocrine cell commitment of human pancreatic cells depends on the 
coordinated action of a TF network, including NEUROG3, FOXA2, PDX1, PTF1A and 
NKX6-1 [38, 52]. Remarkably, PDX1 is described to be broadly expressed in pancreatic 
progenitors and to continue to be expressed during adulthood [38]. 
 
c) Zebrafish as a model organism to study pancreatic development and function 
• Zebrafish as a model organism 
The zebrafish (Danio rerio) presents multiple advantages as a vertebrate model 
organism, when in comparison to mice. It is easy and low-cost to maintain. It has high 
fertility rates. The external fertilization facilitates genetic manipulation and transgenesis 
in embryos, through microinjection [51, 52]. Its development is fast and embryos are 
transparent, allowing the track of fluorescent proteins and organogenesis processes in 
vivo. Additionally, zebrafish shows a short generation time, where fish reach sexual 
maturity within 3 months, which enables to follow heritability and to create stable 
transgenic lines in short timeframes [53]. Finally, the zebrafish genome includes more 
than 26 thousand annotated genes, from which 69% are human orthologous [40]. This 
is accompanied by the conservation of most of developmental processes and gene 
regulatory networks between the two species [52].  
FCUP 
Study of human regulatory mutations associated with pancreatic diseases by humanizing the zebrafish genome. 
13 
 
 
 
Zebrafish transgenesis is very suitable to the study of transcriptional regulation. A 
notable method consists on the validation and characterisation of CREs through cloning 
in shuttle vectors and microinjection of zebrafish embryos [10, 15]. In the case of 
enhancers, the sequence of interest is cloned upstream of a minimal promoter, that alone 
is not able to trigger transcription of an in vivo reporter gene located downstream, such 
as the one encoding a green florescent protein (GFP; [15]). This vector is then integrated 
in the zebrafish genome and if the reporter gene is observed to be expressed, usually 
by direct in vivo microscopic observation, the cloned fragment is validated as an 
enhancer. Other types of CREs can also be easily tested using transgenesis in zebrafish, 
as insulators. In this case, putative insulators are cloned in between an enhancer and a 
promoter located upstream an in vivo reporter gene. Upon the introduction of this vector 
in the zebrafish genome, if the activity of the enhancer is impaired, but not affecting the 
activity of the promoter, the cloned fragment is validated as an insulator [15].   
Further development of transgenesis methods allowed to increase the size of 
potential regulatory genomic fragments. While transgenesis based on small plasmids is 
performed through isolation of the genomic sequence of interest and assessment of its 
regulatory function on the expression of a reporter gene, artificial-chromosome type 
plasmids, such as Bacterial Artificial Chromosomes (BACs), show higher capacity for 
cloned genomic fragments [54]. Integration of larger genomic fragments in model 
organisms, namely zebrafish, is possible due to constitution of transposable elements. 
The most widely used system of transgenesis is based on the cut-and-paste activity of 
the Tol2 transposon [55], leading to high efficient random integrations in the zebrafish 
genome, upon microinjection of one-cell stage zebrafish embryos [56]. BAC 
transgenesis allows to overcome several limitations of transgenesis with small plasmids: 
first, it allows to study regulatory sequences without disturbing their original genomic 
context, highlighting complex gene regulatory mechanisms; moreover, large transgenes 
are associated to more consistent expression levels, showing less unspecific effects due 
to interaction of the transgene with surrounding genomic elements in the host genome 
(referred as “position effect”) [54, 56]. 
Because many of the zebrafish genes are conserved in humans, loss-of-function 
assays have been fundamental to address their function. Mutagenesis, and other types 
of loss-of-function assays of zebrafish genes have been performed in many different 
genetic studies, being a foundation for both forward and reverse genetics. As a relevant 
example to this thesis, O’Hare and colleagues made use of the zebrafish model to 
identify candidate genes that could be directly implicated with T2D. This was performed 
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in zebrafish by the loss-of-function of several candidate genes, known to be located in 
human T2D-associated loci, and analysing its impact in β-cell mass [57]. Thus, zebrafish 
is an extremely reliable model organism to the research of diabetes and to the 
development of new therapies. 
• The zebrafish pancreas 
The zebrafish pancreas presents several common aspects with the pancreas of 
mammals. Phylogenetic studies have shown that the digestive and endocrine systems 
have fused to form the pancreas throughout fish evolution [40]. Zebrafish shares not only 
a conserved pancreatic organization and cellular composition, but also similar 
developmental processes regarding the pancreatic development of mammals [58]. 
The mature zebrafish pancreas reassembles the human organ, consisting on islets 
of endocrine cells dispersed through the acinar cell mass of the exocrine portion [41, 51]. 
In both organisms, the main functions of the endocrine and exocrine pancreas are 
conserved consisting on production of hormones regulating glucose homeostasis and 
digestive enzymes released to the pancreatic ducts, respectively [53].  
The zebrafish pancreas derives from the ventral and dorsal buds, as it happens in 
mammals [53]. The pancreatic buds arise from a Pdx1-expressing cell domain in the 
foregut endoderm. The patterning of the zebrafish embryo foregut correlates with the 
gradient of Pdx1 expression, which together with BMP signalling contributes to determine 
the liver and the pancreatic progenitors. The most exterior 2-cell layer of the foregut gives 
rise to the liver, while the intermediate and most interior layers contribute to the exocrine 
and the endocrine pancreas, respectively [59]. Moreover, the Notch signalling pathway 
implied in pancreatic development of mammals is also conserved in zebrafish. Studies 
performed in a Notch reporter line proved that high levels of this factor correlate with 
quiescence, while low levels primarily lead to the proliferation of progenitors, and 
consequently to cell cycle exit and endocrine differentiation when in continuous 
downregulation [60]. Hnf1ba is also reported to be associated to zebrafish pancreatic 
development, along with the Wnt signaling pathway. In divergence to mice, the zebrafish 
mutant allele hnf1bas430 is known to recapitulate the phenotype of MODY5, a form of 
diabetes arisen from the mutation of the human gene [61].  
Despite the similarities among pancreatic vertebrate development, each organism 
presents particular characteristics. For instance, the cells composing the dorsal bud of 
the zebrafish pancreas are not multipotent cells as in mammals; instead, the lineage 
commitment of the first endocrine progenitor is already restricted to the principal islet 
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[53]. In contrast to mice, the zebrafish endocrine progenitors do not express Neurog3; 
instead, Ascl1b and NeuroD1, two distinct TFs belonging to the same bHLH family, have 
been shown to replace Neurog3 functions. The importance of the cooperative action of 
Ascl1b and NeuroD1 is highlighted by the complete absence of the endocrine pancreas 
upon double knockdown by morpholino [62]. Ascl1b is expressed in both pancreatic buds 
at 10 hpf, where it induces the appearing of the first endocrine progenitors expressing 
Sox4b. Cells expressing both Ascl1b and Sox4b undergo upregulation of NeuroD1 [58]. 
In endocrine progenitors, high and low levels of NeuroD1 determine the differentiation of 
α- and β-cells, correspondingly [63].  
 
d) Pancreatic diseases  
The aetiology of different human pancreatic diseases, is associated to variable 
predisposition traits, from genetic to environmental factors. This is the case of chronic 
pancreatitis, diabetes and pancreatic cancer [41]. Moreover, these complex diseases 
arise from a combined effect of mutations in different loci, which attribute a genetically 
heterogeneous background of susceptibility [64].  
Pancreatic diseases have been broadly associated with mutations on non-coding 
regions of the genome [10, 34]. In particular, non-coding mutations on cis-regulatory 
elements of key pancreatic genes seem to impair the correct gene regulatory networks 
required for normal pancreatic development [7]. Furthermore, some cis-regulatory 
mutations were shown to lead to total absence of the human pancreas [34-36]. 
The mechanisms regulating vertebrate pancreas development have been studied in 
the last decades, namely the gene regulatory networks that were discussed above. 
Although extensively investigated, the molecular and cellular processes implied in 
pancreas morphogenesis and organogenesis remain elusive. For instance, cell fate 
determination and cell polarization during epithelial remodelling and islet has not been 
fully characterised, and is fundamental to understand their impact on pancreatic 
diseases. Further knowledge on gene cis-regulatory mechanisms required for proper 
pancreatic development might help highlighting the impact of cis-regulatory mutations to 
the onset of pancreatic diseases, as well identifying novel therapeutic targets of human 
pathologies, from pancreatitis to diabetes and pancreatic cancer [45, 48]. 
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3) Diabetes mellitus 
Diabetes is a multifactorial disease, being a reflection of the combined effect of 
genetic predisposition, environmental factors, aging and lifestyle [65-67]. The disease 
presents worldwide incidence, being reported to affect more than 422 million adults in 
2016, according to the Global Report On Diabetes from World Health Organization 
(WHO) [68]. When undiagnosed or defectively managed, diabetes can also be 
associated to vascular difficulties, such as cardiovascular disease [67, 68]. 
Diabetes mellitus includes a range of metabolic disorders characterised by 
hyperglycaemia [66, 69]. Hyperglycaemic traits arise from dysregulation of glucose 
homeostasis, which depends essentially on the action of insulin and glucagon through 
feedback mechanisms [1].  
Of note, diabetes seems to be considered as a risk factor for pancreatic 
adenocarcinoma and recent epidemiological studies suggest that the causality also 
works in the reverse direction [41]. This correlation highlights not only the relevance of a 
coordinated function between exocrine and endocrine pancreas, but also the need to 
unravel the molecular mechanisms triggering pancreatic dysfunction. 
 
The first evidence of a correlation among high blood sugar levels and pancreatic 
malfunction was reported in 1889, by Joseph von Mering and Oskar Minkowski [70]. A 
pioneer medical and biochemical investigation regarding pancreatic extracts led to the 
finding of the molecule responsible for glucose homeostatic control [71]. The discovery 
of insulin, in 1921, was attributed to Frederick Banting and Charles Best, a finding 
awarded with the Nobel Prize in Physiology, in 1923 [70]. Further studies started to focus 
on the molecular mechanisms underlying insulin production. Diabetes is a world epidemy 
and the disease complexity has been continuously highlighted, with the attribution of 
genetic and environmental susceptibility factors [72].  
 
a) Different forms of diabetes 
Diabetes mellitus is divided in four main forms, differing on the predisposition risk 
factors, age of onset and aetiology [67]. Based on these criteria, diabetes mellitus 
comprises type 1 and type 2 diabetes, gestational diabetes and other specific forms of 
diabetes, including disorders arising from both genetic and non-genetic molecular origins 
[67, 73]. 
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Regarding the last category, first reports on monogenic forms of diabetes are dated 
to the 90s, with the first description of Maturity-onset diabetes of the young (MODY) [74]. 
MODY is a rare autosomal dominant form of diabetes, which is characterised by an onset 
before the age of 25 years [75, 76]. Currently, there are 13 genes associated with this 
disease onset (Table 1), most of them associated to the regulation of insulin secretion 
as a response to glucose bloodstream levels [76]. Consequently, mutations in these 
genes lead to decreased insulin secretion by β‐cells [75, 76]. Recent studies have been 
suggesting that predisposition to MODY is increased by other genetic, as well as 
environmental factors [76, 77]. The implication of different genetic variants in MODY 
pathogenesis, could be used as a tool to the study of multifactorial types of diabetes [76].  
 
Table 1. List of MODY types and associated genes. Data from OMIM – Online Mendelian 
Inheritance in Man [78]. 
Type MODY-associated genes Specific phenotypic traits 
MODY1 Hepatocyte nuclear factor-4-alpha gene (HNF4A)  
MODY2 Glucokinase gene (GCK)  
MODY3 Hepatocyte nuclear factor-1alpha gene (HNF1A)  
MODY4 
Pancreas/duodenum homeobox protein-1 gene 
(PDX1) 
 
MODY5 Hepatic transcription factor-2 (TCF2) 
Atrophy of the pancreas and 
forms of renal disease 
MODY6 Neurogenic differentiation 1 (NEUROD1)  
MODY7 Kruppel-like factor 11 (KLF11)  
MODY8 Carboxyl-ester lipase (CEL) Exocrine dysfunction 
MODY9 Paired box gene 4 (PAX4)  
MODY10 Insulin (INS)  
MODY11 Tyrosine kinase gene (BLK)  
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MODY13 
Potassium voltage-gated channel subfamily J 
member 11 (KCNJ11) 
 
MODY14 
Adaptor protein, phosphotyrosine interacting with 
PH domain and leucine zipper 1 (APPL1) 
 
 
Aside from the monogenic forms, the most represented types of diabetes are 
polygenic, namely type 1 and type 2 diabetes (T2D) [74, 79]. Type 1 diabetes is 
characterised by pancreatic β-cells destruction due to autoimmune dysfunction. Affected 
patients display life-long dependence on insulin administration [67]. Instead, T2D is 
caused by the impairment of normal pancreatic function due to deficient insulin 
production by β-cells or by insulin resistance [57, 66, 69].  
 
b) Type 2 diabetes (T2D) 
Type 2 diabetes (T2D) is thought to affect around 90% of diabetic patients. This 
number seems to be associated to the nature of its exclusion diagnosis – T2D diagnosis 
outcomes from cases of hyperglycaemic patients showing no evidence of autoimmune 
deficiency (distinctive of type 1 diabetes) and no evidence for monogenic forms of 
diabetes [52, 65, 80]. Despite of the high prevalence among diabetic patients, the 
disease complexity makes T2D frequently undiagnosed. Moreover, the molecular 
mechanisms behind T2D are still poorly understood [66, 68]. 
The complex genetic nature of T2D has been confirmed by several Genome-Wide 
Association Studies (GWAS) [65, 66, 80]. GWAS identify single-nucleotide 
polymorphisms (SNPs) linked to phenotypic traits [81]. This type of genome-wide 
analysis allows to understand the combined contribution of several genomic loci to 
diabetes development, along with its association to both coding and non-coding 
sequences [57, 69, 81]. Interestingly, the majority of T2D-associated SNPs are mapped 
to non-coding sequences of the human genome, suggesting that the impact on disease 
development depends on the disruption of epigenetic mechanisms controling gene 
transcription [37]. Recent studies have detailed that these SNPs are enriched in 
chromatin regions that display marks of cis-regulatory elements (CREs), some of which 
showing activity specifically in pancreatic islets [82]. Moreover, the majority of these SNP 
containing non-coding sequences were shown not to be in linkage desiquilibrium with 
coding sequences, meaning that there is no evidence of preferential segregation of those 
non-coding sequences in combination with coding genes [36]. Alltoghether, these 
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colected data indicated that the role played by these SNPs on a disease-associated 
phenotype might be related to cis-regulatory mechanisms [34]. 
Another layer of investigation relates to expression Quantitative Trait Loci (eQTLs) 
[83]. These loci can be defined as genomic regions containing polymorphisms and 
described to influence gene expression levels [34]. Analysis of eQTLs helps to gain 
insights on how sequence variation is linked to changes in gene expression, and 
consequently, having the potential to produce disease related phenotypes [34, 83]. 
Complementing each other, the analysis of eQTLs allows to recognise causal SNPs 
identified in GWAS, that can have functional relevance, especially in the context of 
pathogenic phenotypes [34, 84].  
 
 
4) Pancreatic and duodenal homeobox 1 (PDX1) 
Pancreatic and duodenal homeobox 1 (PDX1), also known as insulin promoter 
factor-1 (IPF1), is a master regulator of pancreatic development and function, which is 
conserved through vertebrates [85]. The human PDX1 gene is composed by an 852 
base pairs (bps) coding sequence, constituting 2 exons, and it is localized in 
chromosome 13 of the human genome. 
The sequence of PDX1 encodes a 283 amino acids (aa) protein. PDX1 protein is a 
TF responsible for the transcriptional activation of several genes, including insulin, 
somatostatin, glucokinase, islet amyloid polypeptide (IAPP) and glucose transporter type 
2 [52]. This protein includes a N-terminal transactivation domain (13-73 aa), followed by 
anti-type hexapeptide (118-123 aa), which is required for the interaction with PBX1. The 
C-terminal region of the protein contains a homeobox domain (149-203 aa), including 3 
helices and a nuclear localization signal (NLS, 197-203 aa). The homeobox on PDX1 
protein is required for DNA-binding, but it also functions as mediator for protein-protein 
interactions between PDX1 and its interactors [86, 87].  
The human PDX1 protein is conserved in vertebrates, including mice and zebrafish. 
Mice Pdx1 shows 80% sequence identity with the human protein, whereas zebrafish 
pdx1 shows 54% of identity (BLAST analysis, [88]). In particular, the homeobox domain, 
a central component regulator of developmental mechanisms throughout eukaryotes, is 
highly conserved among PDX1 orthologous proteins. Notably, the homeodomain of the 
zebrafish pdx1 protein is 95% identical to the one contained within the mammalian 
orthologs [46, 89]. 
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The role of PDX1 in transcriptional regulation relies on the specific targeting of 
genes to be expressed. The mechanism through which PDX1 binds to target genes 
depends on the protein homeodomain – that enables the recognition of A/T-rich 
sequences. One of its direct target genes is insulin, which transcription is enhanced by 
PDX1 in mature islets. In contrast, the occupancy of the insulin promoter in ductal cells 
by a nucleosome seems to be responsible for the inaccessibility of the insulin promoter 
to PDX1 in this cell type [90, 91]. 
 
a) PDX1 on pancreatic development and adult function 
Among different TFs, PDX1 is known to control the initial steps of pancreas 
development and differentiation, as well as maintaining the function of differentiated 
pancreatic cells [53]. Human PDX1 has been described as broadly expressed in 
pancreatic progenitors around 4 weeks post-fertilization and to continues to be 
expressed during adulthood [38]. Following chromatin remodelling driven by pioneer 
factors that act in human embryonic development [92], as FOXA1 and FOXA2, to 
activate several pancreatic enhancers, PDX1 specifically binds to those to determine cell 
lineage fate [52, 85, 93]. Acting downstream of the Notch signalling pathway on 
progenitor cells, PDX1 is required to the differentiation of the endocrine pancreas. Upon 
the differentiation of endocrine cells, PDX1 is expressed in mature β‐cells. This 
expression is crucial to maintain the insulin levels produced by these endocrine cells, 
and consequently, to ensure a proper regulation of glucose homeostasis [93, 94].  
The relevance of PDX1 for pancreas development and adult function is conserved 
in mammals, as well as in other vertebrates including zebrafish [48]. 
 
b) PDX1 association to disease 
The relevance of PDX1 for pancreatic development, as well for proper mature β‐cell 
function, is demonstrated by the phenotypes arising from different mutations in the locus. 
In humans, homozygous mutations of the PDX1 gene totally impair pancreatic 
development, leading to pancreatic agenesis. In case of heterozygous loss of the gene, 
the low levels of PDX1 are associated to MODY type 4 (MODY4), a phenotype also 
associated to frameshift mutations on the gene’s coding sequence. MODY4 is a form of 
diabetes characterised by deficient insulin secretion and dysregulation of glucose 
homeostasis (Table 1). More recently, homozygous hypomorphic PDX1 mutations, 
leading to decreased gene activity, have been correlated with neonatal diabetes. 
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Additionally, mutations on PDX1-binding sites located in cis-regulatory elements that 
control the expression of different loci are correlated to T2D susceptibility [87, 92]. 
Therefore, total loss or partial deletion is sufficient to cause disease, highlighting the 
importance of PDX1 for proper pancreatic function. 
 
Table 2. Phenotypes described as result of mutations on the human PDX1 locus, as well its 
mice and zebrafish orthologs. 
 Human Mice Zebrafish 
PDX1(+/-) 
Defects in insulin 
production and glucose 
homeostasis (MODY4) 
Defects in insulin 
production and glucose 
homeostasis 
Defects in insulin 
production and glucose 
homeostasis 
PDX1(-/-) Pancreatic agenesis Pancreatic agenesis 
Defects in β-cell function 
and diabetes 
 
The phenotypes arising from Pdx1 mutations in vertebrate orthologs resemble the 
ones described in humans (Table 2). In zebrafish and mice, heterozygous Pdx1 mutants 
show defects on insulin production and β-cell survival [87]. Homozygous Pdx1 mutant 
mice fail to develop a pancreas, resulting in organ agenesis, while zebrafish mutants 
manage to develop a pancreas, even though they show endocrine dysfunction and 
diabetic traits [87, 93]. 
 
c) Regulation of PDX1  
Research on the regulatory elements defining Pdx1 expression throughout 
development and in specific cell types, revealed a sequence located approximately 2- 
kb upstream the transcription start site of the mice Pdx1 gene that mediates expression 
in pancreas, stomach and duodenum [95]. This regulatory sequence holds four domains 
– termed areas I, II, III and IV – which are phylogenetically conserved in mammals. Area 
III is involved in pancreas-wide expression of Pdx1 during early bud formation, whereas 
areas I, II and IV were reported to control restricted gene expression in islets during later 
development and in the mature pancreas [96]. Transfection assays performed in human 
β-cell lines showed that areas I, II and IV induce tissue-specific Pdx1 expression in an 
independent manner. The transcriptional regulation of Pdx1 in β-cells is partially 
mediated by TFs implicated in the development of this cell line, such as FoxA2, MafA, 
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Hnf1a and Pdx1 itself [95, 97]. Moreover, regulatory areas I–IV are located in mapped 
regions of open chromatin of β-cells [98]. 
PDX1 regulation is dependent on upstream and downstream co-factors, as well as 
chromatin structure. These aspects influence PDX1 levels on distinct cell types, enabling 
the expression of PDX1 in early progenitors, followed by specific regulation of gene 
expression in high levels in insulin-producing cells and in low levels in certain 
somatostatin-producing and exocrine cells [96].  
Another layer of regulation of PDX1 levels is achieved by post-translation 
modifications, including phosphorylation, sumoylation and glycosylation. For instance, 
upon the action of kinases on specific residues, phosphorylated forms of PDX1 are 
targeted for proteosomal degradation. Moreover, observations suggesting a cytoplasmic 
localization for PDX1 are associated with cytoplasmic sequestration. This regulatory 
mechanism of PDX1 function responds to physiological conditions, also acting in 
pathological conditions, such as oxidative stress seen in cases β-cell dysfunction [99-
101]. 
 
a) Transcriptional regulation by PDX1 
The mechanisms through which PDX1 regulates gene transcription have been 
explored in several studies, the majority of those using mice as model organisms. In 
these studies, Pdx1 is described to bind to other TFs, including NeuroD1, MafA, Hnf1β 
and Nk2 homeobox 2 (Nkx2-2), as well to transcriptional co-activators, such as p300 and 
Bridge 1 [102]. Altogether, the recruitment of co-activators that link Pdx1 to the Pol II 
transcriptional machinery allows the establishment of protein complexes, which enhance 
DNA binding affinity through modulation of DNA conformation [103].  
The tight transcriptional regulation of PDX1, as well as the role of the TF it encodes 
in several regulatory networks remains elusive. Knowledge of PDX1 cis-regulatory 
sequences is essential to understand the complex gene expression patterns of this 
pancreatic master regulator in specific developmental stages and cell types. 
Furthermore, the study of PDX1 transcriptional regulation should allow gaining insight on 
all the pathways in which this gene is implicated, helping to identify more protein 
interactors and the mechanisms through which the dysregulation of PDX1 expression is 
associated to disease. 
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5) Hypothesis and main objectives 
This work aims to increase our understanding of the impact of human cis-regulatory 
mutations in the development of T2D-associated traits by studying a human relevant 
regulatory landscape. Using bioinformatic tools, we selected the locus of PDX1, that is 
associated to a monogenic form of diabetes, MODY4, and that contains a non-coding 
SNP known to be associate to T2D [7]. Our hypothesis is that changes in PDX1 CREs 
might lead to its transcriptional disruption causing pancreatic T2D associated 
phenotypes. To clarify this, we next screened and validated CREs by transgenesis 
reporter assays, contained in the landscape of PDX1, using the zebrafish as an in vivo 
model. Finally, and since the study of CREs out of their genomic context is very limited 
to address their contribution to PDX1 transcription, we aimed to generate a zebrafish 
transgenic line containing the human PDX1 locus with its corresponding regulatory 
landscape. This line will allow to study the contribution of nucleotide modifications in the 
regulatory landscape of PDX1 to its transcription. Therefore, this work included four goals 
to be achieved: 
1. Bioinformatic analysis of loci of interest: T2D-associated SNPs, prediction of 
CREs and analysis of gene function; 
2. Mapping and in vivo validation of CREs within the selected locus; 
3. BAC recombineering in E. coli; 
4. Transposon-mediated BAC transgenesis in zebrafish.  
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Material and Methods 
1. Locus selection 
The selection of a human locus of interest was based on publicly available GWAS 
data; in detail – GWAS datasets from Pasquali, L. et al. (2014), Sun W. et al. (2018), 
Mahajan, A. et al. (2014), O'Hare, E. A. et al. (2014), Mohlke, K.L. & Boehnke, M. (2015) 
and Zhao, W. et al. (2017) were analysed [1-5]. A group of potential loci of interest with 
reported association to glycaemic traits and T2D predisposition was enumerated. 
The obtained list of genes was further annotated with epigenetic markers of 
chromatin state (H3K4me1, H3K4me3, H3K27ac) and binding of CTCF proteins and 
specific pancreatic TFs (PDX1, FOXA2, NKX2.2, MAFB and NKX6.1) using UCSC 
Genome Browser (GRCh36/hg18 /Human) (http://genome-euro.ucsc.edu/), retrieving 
data from Pasquali and colleagues, from the ENCODE project [4, 6, 7] (http://genome-
euro.ucsc.edu/ENCODE/cellTypes.html) and from the Islet Regulome Browser 
(GRCh37/hg19/Human) (http://www.isletregulome.org/isletregulome/). 
The Zebrafish Information Network (ZFIN) (https://zfin.org/) was employed to search 
for zebrafish orthologues of the candidate genes [104]. UCSC Genome Browser was 
used to explore BAC clone libraries retrieved from NCBI Clone DB database [105].  
 
2. Zebrafish maintenance and microinjection 
a) Zebrafish facility and husbandry 
Zebrafish adults were maintained in the i3S zebrafish facility, under controlled 
abiotic and biotic parameters, in a recirculating housing system. Adult animals in the 
facility are kept in 3,5 L water tanks, at a density of 5 adults/L, and they are fed two to 
three times a day. Zebrafish larvae are kept in smaller tanks at a density of 40 larvae/L. 
The photoperiod is defined by a daily cycle of 14 hours of light and 10 hours of darkness. 
Several water parameters are automatically regulated by a WTU equipment – water 
temperature (26-27ºC), conductivity (0-5g/L) and pH (6,8-8,5). The recirculating housing 
system includes mechanic, chemical and biological filters. 
Rearing, housing and experiments on zebrafish animals were conducted following 
ethical guidelines and minimizing animal stress and suffering [53]. The i3S animal facility 
and the research project are licensed by the Direcção Geral de Alimentação e Veterinária 
(DGAV). Protocols followed were approved by the i3S Animal Welfare and Ethics Review 
Body. 
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b) Zebrafish breeding and embryos collection 
Crossing of adult zebrafish was conducted on breeding cages containing an interior 
cage with a bottom mesh. During late afternoon, males and females were placed in 
breeding cages, in a proportion of 1:2, respectively, and separated by a partition. In the 
morning of the day after, the partition was removed. The breeding tank was placed in a 
slanted position and under direct light, to instigate reproduction. After spawning, fertilized 
eggs were collected by filtering the water in each cage with a net. Embryo collection was 
completed within 20 minutes (min) after partition removal, in order to collect batches of 
synchronized embryos at the 1-cell-stage of development (used for microinjection). 
Zebrafish embryos were maintained in E3 medium – 5 mM NaCl, 0,17 mM KCl, 0,33 
mM CaCl2·2H2O, 0,33mM MgSO4·7H2O and 0,01 % methylene blue (BioChemica, #C.I. 
52015). E3 medium was supplemented with 0.01 % (w/v, weight/volume) PTU (1-phenyl-
2-thiourea) in cases when pigmentation inhibition of the embryos was required. 
 
c) Embryos bleaching and rear of embryos 
Embryos collected from crossing sets in the quarantine room were bleached 
between 10 and 28 hpf. First, a bleach solution at 0,0036 % was prepared, by the diluting 
360 uL of sodium hypochlorite in 1L of distilled water. After that, five washing containers 
were placed in the following order: bleaching solution, tap water, bleaching solution, and 
two more of tap water. During this process, embryos collected in a tea strainer were 
incubated in each bath 5 min. Then, they were transferred to a new Petri dish with E3 
medium and incubated at 28ºC. 
After a period of 5 to 7 days, zebrafish reached the larval developmental stage and 
were placed into the zebrafish facility nursery, where they were fed three times a day. 
Around 3 months after, fish were moved to adult tanks.  
 
d) Microinjection in one-cell stage zebrafish embryos 
Microinjection of zebrafish embryos was performed using the Narishige IM-300 
Microinjector (Tritech Research). Glass capillaries were pulled using Narishige PN-31 
Horizontal Needle Puller (Tritech Research) to generate two glass needles. After the tip 
was cut, the needle was placed in the microinjector and it was filled with the 
microinjection solution. The microinjection solution was previously prepared, containing 
plasmid DNA (concentration dependent on the experiment), Tol2 transposase mRNA at 
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a final concentration of 25 ng/uL and 0,05% of phenol red. Zebrafish fertilized embryos, 
collected as described in Section 2 b), were aligned in Petri plates and injected while in 
one-cell stage. Each embryo was injected with approximately 2-5 nL of microinjection 
solution, estimated by the size of the injected drop. Upon microinjection, embryos were 
incubated at 28,5 ºC in E3 medium with 0,01 % (w/v) PTU. 
 
3. Tol2 transposase mRNA synthesis 
a) Tol2 transposase mRNA transcription in vitro 
The Tol2 transposase was synthetized from the plasmid Tol2-pCS2FA, containing 
Tol2 cDNA (complementary DNA) [106]. The plasmid was transformed into Mach1™ E. 
coli chemically competent bacteria (described in Section 6 a)) and selected in LB agar 
plates containing ampicillin (100 μg/mL, Sigma-Aldrich, #A1593). Isolated colonies were 
picked from the plate to LB liquid medium containing 100 μg/mL of ampicillin and the 
bacterial cultures grew O.N. at 37 °C, with shaking (220 rpm). The plasmid was 
transformed into chemically competent bacteria – described in Section 6 a). Plasmid 
DNA extraction was performed using NZYMiniprep kit (NZYtech, #MB01002), according 
to manufacturer’s instructions. After DNA extraction, the plasmid was linearized by 
digestion O.N. with NotI restriction enzyme (Anza™, #ER0591 – Thermo Fisher 
Scientific) at 37 °C. Reaction mix included 5 uL of plasmid DNA (approximately at 1200 
ng/uL), 1 uL of NotI restriction enzyme (10 U/uL), 2 uL of 10x Anza™ Buffer and 
nuclease-free water up to a final volume of 20 uL. Digestion products were analysed 
through electrophoresis in 1% (w/v) in 1x TAE buffer (Tris-acetate-EDTA) agarose gel 
stained with GreenSafe Premium (NZYtech, #MB13201) and run along with 1 kb DNA 
Ladder (BIORON). Linearized DNA was purified by phenol/chloroform (Section 5), 
followed by quantification by spectrophotometric analysis.  
The linearized and purified Tol2-pCS2FA plasmid was used as template for Tol2 
transposase in vitro transcription. All incubations mentioned hereafter were made at 37 
°C. Transcription reaction mixes were prepared comprising 6,5 uL of HyPure H2O 
(HyClone™ Water, GE Healthcare – Thermo Fisher Scientific), 10 uL of 5x transcription 
buffer, 5 uL of NTP mix (10 mM A, 10 mM U, 10 mM C, 5 mM G) and 5 uL of DTT (50 
mM Dithiothreitol, NZYTech, #MB03101). After an incubation of 5 min, 5 uL of 5’ CAP 
(20-25 mM G(5’)ppp(5’)G RNA Cap Structure Analog; NewEngBiol, #S1407S) were 
added and the reaction was incubated for 1 min. Then, 12 uL of purified Tol2-pCS2FA 
plasmid and 2,5 uL of NZY Ribonuclease Inhibitor (NZYTech, #MB08405) were 
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sequentially added, each followed by 1-min incubations. At this point, 2 uL of RNA 
polymerase SP6 (20 U/µL, ThermoFisher Scientific™, #EP0131) were added and the 
reaction was incubated for 1 hour. Upon incubation, this step was repeated by adding 
more 1 uL of RNA polymerase. Finally, the template DNA was digested by adding 2 uL 
of DNase and incubation for 1 hour. 
 
b) Purification of Tol2 transposase mRNA 
mRNA obtained by in vitro transcription was purified using ProbeQuant™ G-50 
Micro Columns kit (Sigma-Aldrich, GE Healthcare, #GE28-9034-08), following an 
adapted protocol for purification of radiolabelled probes. Starting on the column 
preparation, the resin was resuspended by vortexing. Then, the cap was loosened one-
quarter turn, the bottom closure was removed and the column was placed in the 
collection tube, followed by centrifugation at 735 g for 1 min (VWR Micro Star 17, #521-
1646). Immediately after, the column was placed in a new RNAse free 1,5 mL Eppendorf 
and 50 uL of the newly synthesized RNA were slowly loaded in the column, to the top-
center of the resin. Upon careful loading, the sample was eluted through centrifugation 
at 735 g for 2 min. The RNA sample obtained was then purified by phenol/chloroform 
(Section 5), followed by quantification by spectrophotometric analysis and storing at -80 
ºC. 
 
4. DNA extraction from zebrafish embryos and small fish 
Zebrafish genomic DNA (gDNA) was extracted from whole embryos, after collection 
and dechorionation, or small fish. First, embryos were placed in 40 uL of CHELEX 
solution. The CHELEX solution consists in 5% Chelex® 100 sodium form resin (Sigma-
Aldrich, #C7901-25G) diluted in TE buffer (10 mM Tris·Cl pH 8,0; 1 mM EDTA). Then, 5 
uL of proteinase K (10 mg/mL) were added for each embryo into solution and this was 
incubated O.N. at 56 ºC with shaking. After that, the proteinase K was inactivated by 
incubation at 100 ºC for 10 min, followed by vortexing. Before pipetting gDNA to be used 
in PCR reactions, the samples were briefly centrifuged. Extractions of gDNA were stored 
at -20ºC. 
5. Phenol/Chloroform purification 
Preparations of DNA and RNA were purified with Phenol/Chloroform. Eluted 
DNA/RNA preparations extracted with NZYMiniprep kit (NZYtech) were adjusted to a 
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final volume of 100 uL with HyPure H2O (HyClone™ Water, GE Healthcare – Thermo 
Fisher Scientific), followed by adding 100 uL of Phenol:Chloroform:Isoamyl Alcohol 
(25:24:1, v/v, Invitrogen™, #P3803 – Thermo Fisher Scientific). The mixture was 
vortexed and centrifuged at 13000 rpm for 5 min (VWR Micro Star 17, #521-1646). Upon 
centrifugation, the aqueous phase was transferred to a new RNAse free 1,5 mL 
Eppendorf and mixed with 100 uL of chloroform (Fisher Chemicals). After vortexing, this 
mixture was centrifuged in the same conditions mentioned above. The aqueous phase 
was again collected to a new RNAse free 1,5 mL Eppendorf. DNA/RNA precipitation was 
achieved by adding of 10 uL of Sodium Acetate (AcNa, 3 M, pH 5,6) and 200 uL of ice-
cold ethanol (EtOH, 100 %) per 100 uL of aqueous phase collected, followed by 
incubation of the sample at -20 ºC for 1 hour (minimum time period). The sample was 
then centrifuged at 13000 rpm for 15 min at 4 ºC (VWR Micro Star 17R, #521-1647) and 
the supernatant was discarded. DNA/RNA was washed with ice-cold EtOH 70 %, 
followed by a centrifugation at 13000 rpm for 5 min and removal of the supernatant. 
Pellet was dried out resuspended in 15 uL DEPC-treated H2O.  
Purified DNA/RNA was quantified by spectrophotometric analysis, using NanoDrop 
1000 Spectrophotometer (ThermoFisher Scientific™). DNA preparations were stored at 
-20 ºC and RNA preparations at -80 ºC. 
 
6. Characterization of putative regulatory elements 
a) PCR amplification and subcloning of putative PDX1 CREs 
Human sequences of putative enhancers and insulators were tested for activity 
through in vivo assays in zebrafish. Primers flanking the regulatory elements putative 
sequences were designed (Table 3). Sequences were amplified using the proofreading 
enzyme i-MAX™ II Taq DNA Polymerase (iNtRON Biotechnology, Inc., #25261), suitable 
for TA cloning. PCR reactions were set up comprising 2 uL of 10x PCR buffer, 2 uL of 
dNTP mixture (2,5 mM each), 0,4 uL of forward and reverse primers (10 uM each), 1 uL 
of template DNA (0,1-10 ng/uL), 0,3 uL i-MAX™ II Taq DNA Polymerase (5U/uL) and 
nuclease-free water up to a final volume of 20 uL. As template DNA, the PDX1 BAC and 
a commercially available sample of human genomic DNA (gDNA) obtained from female 
and male anonymous donors were used. PCR amplifications were performed in Veriti 
thermocycler (Applied Biosystems) – this equipment was used in all PCR protocols – 
applying the following conditions: initial denaturation step at 94 °C for 3 min, followed by 
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35 cycles of 94 °C for 30 s, 56-60 °C (depending on the primers melting temperature) for 
45 s and 72 °C for 1 min/kb, and one last extension step of 72 °C for 10 min.  
Table 3. Primers for PCR amplification of PDX1 putative CREs. Forward (FW, 5’-3’) and reverse 
(RV, 3’-5’) primers, employed melting temperatures and amplicon size of indicated regions. 
Primer name Primers’ Tm (°C) Amplicon size (bp) 
en1 PDX1 FW GCAGTAAACAGACTCCAGCC 
60-62 1676 
en1 PDX1 RV AGATAGTGTGGGGTGGGGG 
en2 PDX1 FW AGCCTACACCCCTGGACCC 
58 1532 
en2 PDX1 RV GCAGCCTCCATGTTCTCTTGG 
eSNP PDX1 FW GAAAATATTTAAACAACGCCTGGC 
58 1159 
eSNP PDX1 RV TGGTATCCAGGTCTGAGAGG 
ins1 PDX1 FW CTTAGAAATGCCCCTGCTATGC 
60 1476 
ins1 PDX1 RV GACGCATCTGATGCCAACTGG 
ins2 PDX1 FW CTTGTTGGGAAAAAAAGTCTCCC 
56 795 
ins2 PDX1 RV CAAATCATCCTGGGAAAAAGTAGC 
ins3 PDX1 FW AGTTTTTCCTGTAGGTGGGCT 
56 1143 
ins3 PDX1 RV AATGCCATCAGACACCTGTGA 
 
The PCR amplification was confirmed by running of the PCR product in an 1% (w/v) 
agarose gel stained with GreenSafe Premium (NZYtech, #MB13201), along with 1 kb 
DNA Ladder (BIORON). Loaded agarose gels were visualized by transillumination under 
UV (TFX – 35 M, VILBER LOURMAT). In cases where the PCR product was not specific, 
the fragment of the correct size was extracted from the agarose gel and purified with the 
NZYGelpure (NZYtech, #MB01102), according to the standard protocol. 
Purified PCR products were TA cloned into the entry vector pCR™8/GW/TOPO® 
(Invitrogen™, #250020 – Thermo Fisher Scientific). TOPO® cloning reactions were set 
up according to the standard protocol, comprising 4 uL of fresh PCR product. The 
reaction was incubated for 30 min at room temperature (RT). The cloning reaction was 
followed by transformation of Mach1™ E. coli chemically competent bacteria. A total of 
3 uL of cloning reaction was incubated with 50 uL of competent bacteria for 30 min on 
ice. Cells were exposed to a heat-shock for 30 s at 42 °C, and immediately transferred 
to ice for 2 min. Cells recovery was achieved by addition of 400 uL of Lysogeny Broth 
(LB) and one-hour incubation at 37 °C, with shaking (220 rpm). Cells were plated on LB 
agar plates containing 100 μg/mL of spectinomycin antibiotic (Sigma-Aldrich, #S0692) 
and incubated overnight (O.N.) at 37 °C. Isolated colonies were picked from the plate to 
a liquid medium of 3 mL of LB containing 100 μg/mL of spectinomycin. Liquid cultures 
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grew O.N. at 37 °C, with shaking (220 rpm). Plasmid DNA extraction was performed 
using NZYMiniprep kit (NZYtech), according to manufacturer’s instructions, and stored 
at -20 ºC. 
Presence of the correct fragment into pCR™8/GW/TOPO® plasmid was tested 
through a diagnostic enzymatic reaction with EcoRI (Anza™, #IVGN0116 – Thermo 
Fisher Scientific). Enzymatic reactions included 2 uL of plasmid DNA (200-400 ng/uL), 
0,3 uL of EcoRI restriction enzyme (20 U/uL), 2 uL of 10x Anza™ Buffer and nuclease-
free water up to a final volume of 20 uL. Digestion reactions occurred for 2 hours at 37 
°C and the digestion products were analysed through electrophoresis in an 1% (w/v) in 
1x TAE agarose gel stained with GreenSafe Premium (NZYtech, #MB13201), run along 
with 1 kb DNA Ladder (BIORON). Loaded agarose gels were visualized by 
transillumination under UV (TFX – 35 M, VILBER LOURMAT). Validation of the correct 
fragment was further confirmed by Sanger sequencing using the following primers: M13 
forward (5’-TGTAAAACGACGGCCAGT-3’) and M13 reverse (5’-
TCAGGAAACAGCTATGAC-3’). Sequencing reactions were carried out by the in-house 
Genomics Core Facility – GenCore. Sequence alignment of the results was performed 
on Benchling ([Biology Software]. (2019). https://benchling.com). 
 
b) Recombineering from pCR™8/GW/TOPO® into destination vector 
The putative enhancer and insulator sequences subcloned into 
pCR™8/GW/TOPO® plasmid were recombined into a destination vector, using a 
Gateway® recombination strategy. Putative enhancers were recombined into the Z48 
vector [39] and putative insulators were recombined into the insulator test vector [15].  
Recombination was performed with Gateway® LR Clonase® II Enzyme mix 
(Invitrogen™, #11791020 – Thermo Fisher Scientific). The recombination reaction was 
set up to a final volume of 2,5 µL, containing 1 µL of entry vector (50 ng/µL), 1 µL of 
destination vector (50 ng/µL) and 0,5 µL of Clonase® II Enzyme mix. Reaction mixes 
were incubated in the thermocycler (Veriti, Applied Biosystems) for 1 hour at 25 ºC. The 
reaction was stopped upon adding of 0,25 µL of Proteinase K solution (2 µg/µl) and 
incubation for 10 min at 37ºC. The product of recombination was used to transform 
Mach1™ E. coli chemically competent bacteria, as it is described in section 5 a). Cells 
were plated on LB agar plates containing 100 μg/mL of ampicillin antibiotic (Sigma-
Aldrich, #A1593) and incubated O.N. at 37 °C. Isolated colonies were picked from the 
plate to a liquid medium of 3 mL of LB containing 100 μg/mL of ampicillin. Liquid cultures 
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grew O.N. at 37 °C, with shaking (220 rpm). Plasmid DNA extraction was performed 
using NZYMiniprep kit (NZYtech), according to manufacturer’s instructions, and stored 
at -20 ºC. 
(1) Z48 vector recombination 
The Z48 vector (Figure 3A) contains a Green Fluorescent Protein (GFP) reporter 
gene under the control of a minimal promoter. The Z48 enhancer, cloned upstream the 
minimal promoter, drives GFP expression in zebrafish midbrain, working as internal 
control of transgenesis [107]. A Gateway® site located between the Z48 enhancer and 
the minimal promoter allows to recombine the putative enhancer sequence from 
pCR™8/GW/TOPO® to this destination vector.  
(2) Insulator test vector recombination 
The insulator test vector (Figure 3B) contains a GFP reporter gene under a 
Cardiac Actin promoter, which drives GFP expression in muscle cells. The Z48 enhancer 
is located upstream of a Gateway® site, that is followed by the Cardiac Actin promoter. 
The Gateway® site allows to recombine the putative insulator sequence from 
pCR™8/GW/TOPO® (entry vector) to this vector. After microinjection in one-cell stage 
zebrafish embryos, insulator activity can be accessed through compared analysis of Z48-
mediated GFP expression in the midbrain and GFP expression in muscle cells. 
 
 
Figure 3. Vectors for detection of cis-regulatory elements. The vectors are transposable elements 
in the presence of Tol2 transposase [102], as they contain Tol2 recognition sites flanking the region of 
interest. Each vector contains a minimal promoter, the Cardiac Actin promoter, driving expression of GFP in 
the somites of transgenic embryos. The transposons also include a midbrain-specific enhancer, the Z48 
enhancer, which drives strong GFP expression in the midbrain. A. The Z48 vector contains a Gateway® 
cloning site upstream the minimal promoter. When the vector is empty, GFP expression is detected in 
midbrain and somites. The insertion of an active tissue-specific enhancer in the cloning site leads to GFP 
expression in that tissue. B. The insulator test vector comprises the Z48 enhancer upstream the GW cloning 
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site, followed by the minimal promoter. The empty vector induces a similar GFP expression pattern to the 
empty Z48 vector. Upon cloning of a strong insulator, GFP expression in the midbrain is significantly 
decreased, due to blocking of activity by the Z48 enhancer over the promoter. 
 
c) Microinjection of vectors for detection of cis-regulatory elements in zebrafish 
embryos 
The Z48 vector containing the putative enhancers and the insulator test vector 
containing the putative insulators were microinjected in one-cell stage zebrafish 
embryos, as described in Section 2 d). In this assay, the following zebrafish lines used 
were the following: the transgenic line tg(sst:mCherry) for testing of putative enhancers 
and the wt animals for testing of putative insulators. Upon microinjection along with Tol2 
transposase mRNA, the transposable element flanked by the Tol2 recognition sites is 
integrated into the zebrafish genome. 
Each microinjection solution was prepared containing the plasmid DNA and the Tol2 
transposase mRNA, both at a final concentration of 25 ng/uL, and 0,05% of phenol red. 
After microinjection, embryos were incubated at 28,5 ºC in E3 medium supplemented 
with 0,01 % (w/v) PTU. 
 
7. Immunohistochemistry and immunostaining of zebrafish embryos 
Enhancer activity was evaluated by immunohistochemistry for pancreatic markers. 
Embryos at a developmental stage of 36 hpf were dechorionated and fixed O.N. at 4 ºC 
in formaldehyde 4 % in PBS – Phosphate-Buffered Saline, 1x. Upon fixation, all washes 
and incubations were done with shaking. Fixed embryos were washed in 0,1 % Triton X-
100 in PBS-1x (PBS-T) for 5 min at RT, followed by a 2 hours permeabilization with 1 % 
PBS-T at RT. Then, embryos were washed once more in 0,1 % PBS-T (0,1 % Triton X-
100 in PBS-1x) for 5 min at RT and blocking was performed with 5% BSA-PBS-T (5% 
Bovine Serum Albumin in 0,1% PBS-T) for 1 hour at RT. After the blocking, 
immunohistochemistry was performed by incubation of the embryos with anti-Nkx6.1 
(1:75, Hybridoma Bank, #F55A10) primary antibody diluted in 5% BSA-PBS-T, 
throughout 36 hours at 4 ºC. This step was followed by 6 washes of 10 min each in 0,1 
% PBS-T at RT. Then, the embryos were incubated with DAPI (1:1000, Invitrogen, 
#D1306) and the anti-Mouse Alexa Fluor® 647 (1:800, Invitrogen, #A21236) secondary 
antibody diluted in 5% BSA-PBS-T (O.N. at 4 ºC). Finally, embryos were washed at RT 
for periods of 10 min in 0,1 % PBS-T at RT, followed by a final wash of 30 min. Upon 
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removal of the washing solution, the embryos were stored in 50 % glycerol in PBS-1x at 
4 ºC.  
Microscopy slides were prepared by removing the yolk of the embryos and mounting 
them on 50 % glycerol in PBS-1x. Imaging analysis was performed in a SP5II Leica 
confocal microscope. Confocal images were processed with ImageJ software [108].  
 
8. Fluorescence quantification of zebrafish embryos in vivo  
Embryos with 24 hpf were dechorionated. During the documentation process, 
embryos were anaesthetized by adding 100-200 mg/L of MS-222 anaesthetic agent, also 
termed tricaine, (ethyl 3-aminobenzoate methane-sulfonate salt, Sigma-Aldrich, #A5040) 
to the E3 medium where the embryos were incubated. Between 10 and 30 zebrafish 
embryos were analysed and photographed in a Leica M205 stereomicroscope. 
Photographs were taken in 3 % agarose plates, by dilution of agarose in E3 medium. 
Image analysis and fluorescence quantification was performed using the Fiji software 
from ImageJ [109]. 
 
9. Humanization of the zebrafish genome 
a) BAC clone extraction and confirmation 
BAC clone libraries retrieved from NCBI Clone DB database were explored in UCSC 
Genome Browser (GRCh38/hg38/Human) (http://genome-euro.ucsc.edu/), as it was 
mentioned in Section 1 [7]. BAC clone CH17-423D7 from CHORI-17: Hydatidiform Mole 
(Homo sapiens) BAC Library was selected (position chr13:27,763,911-27,985,654, 
GRCh38/hg38/Human). The clone was purchased online from BACPAC Resources 
Center (BPRC) (https://bacpacresources.org/), at Children's Hospital Oakland Research 
Institute in Oakland, California, USA. BAC clones from the hydatidiform mole were 
created at BACPAC Resources by Drs. Mikhail Nefedov & Pieter J. de Jong using a cell 
line created by Dr. Urvashi Surti. 
The CH17-423D7 BAC (henceforward referred as PDX1 BAC) was extracted from 
the original bacterial strain sent from BPRC. High-quality BAC DNA was prepared and 
purified using NucleoBond® BAC 100 kit (#740579, Macherey-Nagel GmbH & Co. KG), 
following manufacturer’s instructions. Purified BAC DNA was quantified by 
spectrophotometric analysis, using NanoDrop 1000 Spectrophotometer (Thermo Fisher 
Scientific).  
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BAD DNA integrity was confirmed by electrophoresis in 1% (w/v) agarose gel 
stained with GreenSafe Premium (NZYtech, #MB13201), run along with Lambda 
DNA/HindIII Marker (Thermo Scientific™, #SM0101).  
Validation of the correct human genomic sequence in the BAC was confirmed by 
PCR amplification with primers flanking the putative regulatory elements sequences 
selected before (Table 6). Sequences were amplified using NZYTaq II 2× Green Master 
Mix (NZYtech, #MB35802). PCR reactions were set up accordingly to the standard PCR 
mix, including 0,1 uL BAC template (10 ng/uL). PCR conditions were as follows: initial 
denaturation step at 95 °C for 3 min; 35 cycles of 94 °C for 30 s, 56-60 °C (depending 
on the primers melting temperature) for 30 s and 72 °C for 1 minute/kb; and final 
extension step of 72 °C for 5 min. PCR amplification was confirmed by electrophoresis 
in 1% (w/v) agarose gel stained with GreenSafe Premium (NZYtech, #MB13201), along 
with 1 kb DNA Ladder (BIORON). 
 
b) PDX1 BAC recombineering 
(1) BAC electroporation 
In order to perform recombineering, PDX1 BAC was transformed into the 
recombinogenic bacteria SW102, purchased from National Cancer Institute (NCI-
Frederick) [110]. The bacterial glycerol stock of E. coli SW102 was streaked in a LB agar 
plate and incubated O.N. at 32°C. Cells were then streaked to LB agar plates containing 
12,5 μg/mL of tetracycline antibiotic (Sigma-Aldrich, #87128) and incubated O.N. at 
32°C. Isolated colonies were picked from the plate to LB liquid medium containing 12,5 
μg/mL of tetracycline. Liquid cultures grew O.N. at 32 °C, with shaking (220 rpm) and 
isolated from direct light – due to antibiotic light sensitivity. Liquid cultures were used to 
prepare glycerol stocks with sterile 25 % glycerol diluted in double-distilled water (ddH2O) 
(Sigma-Aldrich, #G9012). 
Electrocompetent E. coli SW102 cells were prepared from the above-mentioned 
liquid cultures. After O.N. growth at 32 °C, 1 mL of liquid culture was diluted in 100 mL 
LB containing 12,5 μg/mL of tetracycline (1:100). Cells were grown at 32 °C to an OD600nm 
of 0,4-0,5, followed by cooling on ice-water bath for 20 min. Cells were kept on ice until 
electroporation during the following steps. Cells were transferred to two pre-chilled 50 
mL Falcon tubes (BD Biosciences) and harvested by centrifugation at 4000 rpm for 10 
min at 4 °C (Refrigerated Centrifuge Sigma 3k15 – Sigma-Aldrich). Upon centrifugation, 
the supernatant was removed and each pellet was resuspended in 50 mL of 10 % ice-
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cold glycerol. Three washing cycles with centrifugation and resuspension on glycerol 
were followed, with increasing centrifugation speeds (5000 rpm, 6500 rpm and 8000rpm 
sequentially). The supernatant was decanted leaving around 1 mL of glycerol, where 
cells were gently resuspended by stirring and kept at 4 °C until electroporation. 
An aliquot of 40 uL of electrocompetent cells was used for each electroporation in a 
pre-chilled 0,1 cm cuvette (Bio-Rad, #1652089). Cells were previously mixed with 
purified plasmid DNA and incubated for 5-10 min at 4 °C. Plasmid DNA concentrations 
tested ranged between 200 ng and 1 ug, in a final volume of 1 to 5 uL. Electroporation 
was performed in the Gene Pulser® Electroporation System (Bio-Rad) and the conditions 
tested were the following: 25 mF, 1,2-1,8 kV and 200 Ω. After electroporation, cells were 
recovered by adding of 1 mL of pre-warmed LB, transferring to a 15 ml Falcon tube and 
incubation at 32 °C for 2 hours with shaking (220 rpm). Cells were plated on LB-
chloramphenicol agar plates (12,5 ug/mL) and incubated O.N. at 32 °C. A known amount 
of supercoiled pD274 (2,8 kb) plasmid was transformed, followed by cells recovery and 
plating on LB agar plates containing 100 ug/mL of kanamycin antibiotic (Sigma-Aldrich, 
#BP861). The resulting colonies were counted in order to assess the efficiency of 
electrocompetent bacteria, calculated as number of transformed bacteria per microgram 
of DNA. 
Bacterial clones grown on selective plates with chloramphenicol were confirmed for 
the presence of the BAC by colony PCR. The set of primers designed to amplify the 
putative regulatory elements selected above were used (Table 6). PCR amplification 
was performed using NZYTaq II 2× Green Master Mix (NZYtech, #MB35802). Reactions 
were prepared accordingly to the standard PCR mix, followed by the picking of single 
colonies to each PCR reaction. Amplification was performed with the following 
conditions: initial denaturation step at 95 °C for 3 min; 35 cycles of 94 °C for 30 s, 56-60 
°C for 30 s and 72 °C for 1 minute/kb; and final extension step of 72 °C for 5 min. PCR 
amplification was confirmed by electrophoresis in 1% (w/v) agarose gel stained with 
GreenSafe Premium (NZYtech, #MB13201), along with 1 kb DNA Ladder (BIORON). 
Additionally, single colonies of E. coli SW102 cells containing the BAC 
(SW102:BAC) were tested through antibiotic selection in LB agar plates containing both 
chloramphenicol and tetracycline antibiotics (12,5 μg/mL and 100 μg/mL, respectively).  
(2) PCR amplification of Tol2 cassette 
Taking advantage of the recombinase functions of the E. coli SW102 strain, a 
cassette containing the minimal sequences required for Tol2 transposition in zebrafish 
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was placed inside the PDX1 BAC. The cassette includes an ampicillin resistance gene 
flanked by the Tol2 recognition sequences, allowing antibiotic selection. Primers to 
amplify the Tol2 cassette were designed, each comprising a 5’ sequence of 50 base 
pairs (bps) with homology to the target site on the backbone of the BAC – an attB1 site. 
Primers used were the following: 5’-cgtaagcggggcacatttcattacctctttctccgca 
cccgacatagataCCCTGCTCGAGCCGGGCCCAAGTG-3’ and 5’-cggggcatgactattggcg 
cgccggatcgatccttaattaagtctactagATTATGATCCTCTAGATCAGATCT-3’. The plasmid 
pCR8GW-iTol2, kindly sent by Professor K. Kawakami, was used as template for PCR 
amplification. The Tol2 cassette was amplified using the proofreading enzyme i-MAX™ 
II Taq DNA Polymerase (iNtRON Biotechnology, Inc., #25261). PCR reactions were set 
up comprising 10 uL of 10x PCR buffer, 8 uL of dNTP mixture (2.5mM each), 5 uL of 
forward and reverse primers (10 uM each), 1 uL of template DNA (10 pg/uL), 0,7 uL i-
MAX™ II Taq DNA Polymerase (5U/uL) and nuclease-free water up to a final volume of 
100 uL. PCR amplifications were performed applying the following conditions: an initial 
denaturation step at 94 °C for 2 min, followed by 35 cycles of 94 °C for 30 s , 58 °C  for 
30 s and 72 °C for 1 minute/kb, and one last extension step of 72 °C for 5 min. PCR 
amplification was confirmed by running 1/10 of the PCR product in an 1% (w/v) agarose 
gel stained with GreenSafe Premium (NZYtech, #MB13201), along with 1 kb DNA 
Ladder (BIORON). Complete digestion of the template plasmid was ensured by adding 
2 uL of DpnI restriction enzyme to the PCR reaction and an O.N. incubation at 37 °C. At 
last, the PCR product was purified using the NZYGelpure (NZYtech, #MB01102), 
according to the standard protocol. The purified Tol2 cassette was quantified by 
spectrophotometric analysis, using NanoDrop 1000 Spectrophotometer (Thermo Fisher 
Scientific). 
(3) BAC recombineering of the Tol2 cassette 
The term “recombineering” stands for recombination-mediated genetic engineering, 
referring to an in vivo technique of genetic manipulation [63, 64]. This method allows 
modifying DNA sequences via homologous recombination performed by bacteria, which 
displays several advantages in comparison to classical cloning methods, when 
necessary to manipulate large sequences [61]. E. coli SW102 genome contains a Red 
recombinase system with three λ Red-encoded genes, regulated by a heat-shock 
inducible promoter. The three genes comprise gam, bet and exo – gam encodes a 
protein responsible for preventing the destruction of the exogenous DNA fragments by 
endonucleases, bet encodes a protein that promotes the annealing between 
complementary single-stranded DNA sequences and exo encodes an exonuclease with 
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5’ to 3’ activity able to produce 3’ overhangs, enabling recombination of homologous 
fragments [63, 64]. This system induces recombinase functions after transformation of 
bacteria containing a BAC DNA (in this case, PDX1 BAC) with a donor DNA sequence 
flanked by homologous sequences to the target site of recombineering. 
To perform recombineering, electrocompetent E. coli SW102:BAC cells were 
prepared from the positive single colonies selected in section 9 b) (2). Isolated colonies 
were picked from the plate to LB medium containing chloramphenicol and tetracycline 
(12,5 μg/mL and 100 μg/mL, respectively) and liquid cultures grew O.N. at 32 °C, with 
shaking (220 rpm) and isolated from direct light. The day after, 1 mL of O.N. culture was 
diluted in 100 mL of LB-chloramphenicol-tetracycline (12,5 μg/mL and 100 μg/mL, 
respectively). Cells were grown at 32 °C to an OD600nm of 0,4-0,5, followed by a heat-
shock at 42 °C for exactly 15 min, with manual shaking, to induce recombinase functions. 
Upon heat-shock, cells were immediately transferred to an ice/water slush and left to 
cool for 10 min. Cells were treated accordingly to the protocol mentioned in section 9 b) 
(1). After the last centrifugation step, cells were resuspended in 1 mL of 10 % glycerol 
and kept at 4 °C until electroporation. 
Aliquots of 40 uL of freshly-prepared electrocompetent cells were mixed with the 
purified Tol2 cassette (3,5–700 ng), along with the competence control test. 
Electroporation was performed as mentioned in section 9 b) (1). Cells were plated on LB 
agar selective plates, containing chloramphenicol and ampicillin (12,5 μg/mL and 100 
μg/mL, respectively), and incubated O.N. at 32 °C. 
(4) Selection and preparation of BAC-Tol2 construct 
Single colonies of E. coli SW102 cells grown on LB-chloramphenicol-ampicillin 
plates (12,5 μg/mL and 100 μg/mL, respectively) were confirmed for recombineering 
through colony PCR and antibiotic resistance.  
Colony PCR was performed with two pairs of primers. Two primers were designed 
flanking the target site on the BAC where the Tol2 cassette is placed in case of 
recombination (BAC REC primers for colony PCR A). Additionally, a forward primer was 
designed to the ampicillin resistance gene of the Tol2 cassette and used together with 
the previously mentioned reverse primer on the homology region. PCR amplification was 
performed using NZYTaq II 2× Green Master Mix (NZYtech, #MB35802). Reactions were 
set up comprising the standard PCR mix, followed by picking of single colonies. 
Amplification was performed with the following PCR conditions: initial denaturation step 
at 95 °C for 3 min; 35 cycles of 94 °C for 30 s, 60 or 65 °C for 30 s and 72 °C for 1 min/kb; 
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and final extension at 72 °C for 5 min. PCR amplification was confirmed by 
electrophoresis in 1% (w/v) agarose gel stained with GreenSafe Premium (NZYtech, 
#MB13201), along with 1 kb DNA Ladder (BIORON). 
Antibiotic selection of E. coli SW102 cells containing the BAC-Tol2 construct 
(SW102:BAC-Tol2) was achieved by streaking of single colonies on LB-
chloramphenicol-tetracycline (12,5 μg/mL each) and LB- chloramphenicol-tetracycline-
ampicillin (12,5 μg/mL, 12,5 μg/mL and 100 μg/mL, respectively) agar plates. Incidence 
of false positives was also verified by streak of single colonies on LB-spectinomycin (100 
μg/mL) agar plates, the resistance present in the backbone of the plasmid used as 
template for the amplification of the Tol2 cassette. 
Upon selection of positive colonies for Tol2 cassette recombination into the BAC, 
plasmid DNA was extracted and purified using NucleoBond® BAC 100 kit (#740579, 
Macherey-Nagel GmbH & Co. KG), following manufacturer’s instructions. Quantification 
was performed by spectrophotometric analysis, using NanoDrop 1000 
Spectrophotometer (Thermo Fisher Scientific). The integrity of the BAC-Tol2 construct 
was confirmed by electrophoresis in 1% (w/v) agarose gel stained with GreenSafe 
Premium (NZYtech, #MB13201), run along with Lambda DNA/HindIII Marker (Thermo 
Scientific™, #SM0101). Furthermore, the construct was purified by Phenol/Chloroform, 
as it is described in Section 5.  
 
c) BAC transgenesis in zebrafish 
(1) Zebrafish pdx1 mutant: genotyping and expanding the line 
A zebrafish mutant line for the pdx1 locus was reared in the husbandry of the i3S 
zebrafish facility, according to ethical guidelines and standard protocols [53]. A zebrafish 
mutant line holding pdx1 mutant allele designated pdx1sa280/sa280, generated through the 
Zebrafish Mutation Project, was kindly sent by Professor Robin A. Kimmel [111]. The 
zebrafish line was characterised by Kimmel, R. A. and colleagues [93]. The pdx1 mutant 
allele yields a transcript containing a premature stop at codon (Y37X), located within the 
protein highly conserved N-terminal transactivation domain. 
The offspring of the incross between two heterozygous animals for the pdx1sa280 
allele was reared in the husbandry of the facility. When the offspring reached sexual 
maturity, animals were genotyped through an outcross with wild-type (wt) animals. The 
offspring of this outcross was then genotyped by DNA extraction of 8 embryos batches 
(Section 4), following Kimmel, R. A. and colleagues’ recommendations [93]. The pdx1 
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locus was amplified with the following primers: forward 5’-
CCCCAACGAAGACTACAGCC-3’ and 5’-ATGGCCTGCAATCAGGAGTTA-3’. The 
PCR reaction was performed using NZYTaq II 2× Green Master Mix (NZYtech, 
#MB35802), preparing the standard PCR mix. PCR conditions were the following: 95 °C 
for 3 min; 35 cycles of 94 °C for 30 s, 61 °C for 30 s and 72 °C for 30 s; and 72 °C for 5 
min. After confirming the amplification on a 1% (w/v) agarose gel, the PCR product was 
digested with DraI restriction enzyme (Thermo Fisher Scientific™, #ER0221). Enzymatic 
reactions included 3 uL of PCR product, 1 uL of DraI (10 U/uL), 2 uL of 10x Buffer Tango 
and nuclease-free water up to a final volume of 20 uL. A negative control for the 
enzymatic reaction was performed along, preparing the same reaction but without DraI 
restriction enzyme. Digestion reactions occurred O.N. at 37 °C and the final product was 
analysed in an 2 % (w/v) agarose gel stained with GreenSafe Premium (NZYtech, 
#MB13201), run along with 1 kb DNA Ladder (BIORON). 
(2) BAC microinjection and viability assays 
The purified BAC-Tol2 construct was microinjected in one-cell stage zebrafish 
embryos, as described in Section 2 d). In this assay, the following zebrafish lines used 
were following: the pdx1 mutant line with the sa280 allele and the WT line from the i3S 
facility.  
Each microinjection solution was prepared containing the plasmid DNA at final 
concentration ranging from 50 to 500 ng/uL, Tol2 transposase mRNA at a final 
concentration of 25 ng/uL and 0,05% of phenol red. After microinjection, embryos were 
incubated at 28,5 ºC in E3 medium.  
Zebrafish embryos microinjected with the BAC-Tol2 construct were analysed at 24 
and 48 hpf to assess viability. The surviving embryos were bleached as described in 
Section 2 c) and reared in the i3S zebrafish facility (ongoing).  
(3) Genotyping BAC transgenesis 
Samples of gDNA extracted from batches of four zebrafish individuals with 10 days 
post-fertilization (dpf) microinjected with the PDX1 BAC were used for PCR amplification. 
Primers designed to bind specifically to the promoter of the human PDX1 locus were 
used to evaluate integration of the human transposon into the zebrafish genome. Primers 
used were the following: BAC genotyping forward (5’-AGCCTCTGCTTCAGCTTCTG-3’) 
and BAC genotyping reverse (5’-GGTGCAGAAACAAGCCTCTC-3’). 
As controls, PCR reactions containing zebrafish DNA mixed with the PDX1 BAC 
were performed. To define a minimum threshold in which the human PDX1 locus could 
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be detected within zebrafish genome, the amount of BAC DNA employed in PCR 
reactions was estimated to mimic the event of a single molecule insertion of the human 
PDX1 BAC into the zebrafish genome. Taking into account that the full sizes of the 
zebrafish genome and the PDX1 BAC molecule are ~1,7x109 and ~3x105 bp, 
respectively [105, 112], the zebrafish genome is approximately 104 larger than the BAC 
molecule. Therefore, PCR reactions containing mixtures of zebrafish and BAC DNA were 
prepared in a proportion of 1:10000. Considering an approximated DNA concentration 
of 10 ng/uL in zebrafish DNA extraction, each reaction was prepared mixing 1 uL of 
zebrafish DNA with 1 pg of BAC. Further dilutions of the same zebrafish DNA sample 
with 10 fg and 1 fg of BAC were also prepared to ensure sufficient resolution to mimic 
the presence of 1 BAC copy in 100 and 1000 zebrafish genome copies, respectively. 
Mixes are later addressed as “1 BAC + 1 ZF”, “1 BAC + 100 ZF” and “1 BAC + 1000 ZF”. 
PCR amplification was performed using NZYTaq II 2× Green Master Mix (NZYtech, 
#MB35802). Reactions were prepared accordingly to the standard PCR mix and 
amplification was performed with the following conditions: initial denaturation step at 95 
°C for 3 min; 35 or 40 cycles of 94 °C for 30 s, 56-60 °C for 30 s and 72 °C for 1 minute/kb; 
and final extension step of 72 °C for 5 min. PCR amplification was confirmed by 
electrophoresis in 1% (w/v) agarose gel stained with GreenSafe Premium (NZYtech, 
#MB13201), along with 1 kb DNA Ladder (BIORON).  
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Results and Discussion 
1. Candidates selection 
To select our locus of interest, GWAS datasets that describe human SNPs linked to 
glycaemic traits and T2D predisposition (see Materials and Methods) were collected, 
excluding SNPs identified in coding regions. A total of different 126 SNPs potentially 
impacting on disease susceptibility was listed (Supplementary Table 1). Then, a series 
of guidelines was followed to select a single candidate locus from the compiled data.  
The first selection criterion was the sorting of SNPs co-localizing with epigenetic 
marks characterising enhancer elements, thus potentially determining disease 
susceptibility through cis-regulatory mechanisms. Therefore, we carefully analysed 
histone modifications – namely H3K4me1 and H3K27ac – detected by ChIP-Seq. 
H3K4me3 epigenetic mark was also evaluated in order to distinguish regions 
simultaneously enriched in H3K4 mono- and tri-methylation marks present at gene 
promoters. Islet-specific TFBS identified both in human pancreatic progenitor cells and 
adult pancreatic islets were explored in the Islet Regulome browser and their ChIP-Seq 
tracks analysed [7, 23, 39]. Regarding the TFs screening, it is noteworthy to mention the 
work of Pasquali et al. in which authors demonstrate that crucial genes regulating 
pancreatic function of adult lineages as well as pancreas homeostasis are bound by a 
fraction or all of a cluster of islet TFs. This cluster includes PDX1, MAFB, NKX6.1, 
FOXA2 and NKX2.2 [7]. This way, screening for their concomitant signature was 
employed as first criterion along with epigenetic marks. 
The second sorting step consisted in assigning every SNP to a specific gene 
according to genomic proximity, assuming that SNPs potentially modulate gene´s 
transcription. Moreover, by bibliographic review, all the SNPs already annotated to be 
associated to differences in expression of a single gene or locus (linkage disequilibrium) 
were included. Analysis of genomic localization of SNPs and nearby genes was 
performed using UCSC Genome Browser (GRCh37/hg19/Human; see Material and 
Methods). Genes and associated SNPs were sorted setting an upper limit of 150 kb of 
genomic distance among the two elements. This analysis aims to ensure that the 
genomic region of interest could be included in a BAC, that usually have a capacity limit 
of 300 kb [56]. As we intend to gain knowledge on the impact of human regulatory SNPs 
on a diabetes-like phenotype through functional studies, we sorted the enumerated 
SNPs according to their linkage to key-pancreatic genes. Namely, special attention was 
given to genes previously described to have functional relevance for pancreatic 
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development and function, such as MODY-associated genes. The previously mentioned 
series of criterions resulted in a list of 19 candidate loci (Table 4). 
Table 4. List of 19 candidate loci defined as potential loci of interest. The list enumerates: T2D-
associated SNPs retrieved from GWAS datasets; genes located nearby those SNPs, accompanied by 
number of SNPs per nearby gene; genomic localization coordinates (GRCh37/hg19), length of their coding 
sequences and bibliographic references for T2D-associated SNPs (A - Sun W. et al. 2018;.B - Mahajan et 
al. 2018; C - O'Hare et al. 2014; D - Pasquali et al. 2014; E - Mohlke, K.L. et al. 2015; F - Zhao W. et al 
2017). 
T2D-associated 
SNP 
Nearby gene 
Number of 
SNPs per 
nearby gene 
Genomic localization 
(GRCh37/hg19) 
Length of gene 
coding sequence 
(bps) 
References 
rs7124355 
ABCC8 3 chr11:17,414,432-17,498,449 84018 
A 
rs757110 A 
rs5219 B 
rs7202877 
BCAR1 2 chr16:75262928-75299905 39867 
C 
rs72804106 D 
rs7163757 
C2CD4A 2 chr15:62359176-62363116  3941 
D 
rs7172432 E 
rs7945565 
CRY2 3 chr11:45868957-45904799 35843 
D 
rs7945689 D 
rs1401419 D 
rs73300993 
FOXA2 4 chr20:22561642-22565101 3460 
D 
rs6048202 D 
rs1203898 D 
rs1203899 D 
rs2908286 
GCK 2 chr7:44183870-44198887 53900 
D 
rs4607517 D 
rs8108269 
GIPR 9 chr19:46171502-46185717 14216 
B 
rs1800437 B 
rs11670462 D 
rs55872740 D 
rs10403962 D 
rs10404142 D 
rs10404527 D 
rs10409882 D 
rs8104845 D 
rs11651052 
HNF1B 9 chr17:36046434-36105096 58663 
A 
rs11263763 A 
rs11651755 A 
rs11658063 A 
rs2005705 A 
rs4239217 A 
rs4430796 A 
rs7501939 A 
rs8064454 A 
rs4812829 
HNF4A 2 chr20:42984441-43036115 31590 
C 
rs1884613 A 
rs1002226 
KCNJ11 3 chr11:17406796-17410206 3411 
A 
rs2074314 A 
rs7124355 A 
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rs10842994 
KLHL42 8 chr12:27933187-27955973  22787 
E 
rs12581729 D 
rs10842991 D 
rs10771372 D 
rs3751239 D 
rs10842992 D 
rs10842993 D 
rs11049161 D 
rs11936387 
MAEA 2 chr4:1283672-1333925 50254 
D 
rs6815464 E 
rs12186664 
PCSK1 4 chr5:95726040-95768985 42946 
D 
rs17085593 D 
rs59139497 D 
rs2882298 D 
rs35369009 PDX1 1 chr13:28494168-28500451 6284 D 
rs10510110 
PLEKHA1 2 chr10:124134094-124191871 57778 
B 
rs2421016 E 
rs4925115 SREBF1 1 chr17:17714663-17740325 25663 C 
rs1801214 
WFS1 8 chr4:6271577-6304992 33416 
B 
rs1801212 B 
rs4689388 D 
rs4320200 D 
rs13107806 D 
rs13127445 D 
rs4273545 D 
rs6830765 D 
rs4457053 
ZBED3 4 chr5:76383884-76444176 10499 
E 
rs4457054 D 
rs7708285 D 
rs7732130 D 
rs11634397 
ZFAND6 3 chr15:80351910-80430735 78826 
E 
rs1357335 D 
rs1357336 D 
 
Further selection ensured that candidates have a zebrafish ortholog and availability 
of a BAC clone containing the locus of interest [104, 105]. Among the 19 candidates 
(Table 3), we chose PDX1 as our locus of interest. As addressed in the Introduction, 
PDX1 is a human gene encoding a transcription factor broadly expressed in pancreatic 
progenitors and differentiated pancreatic cells. Proper regulation of PDX1 expression is 
required in the initial stages of pancreatic organogenesis, as well for the determination 
of pancreatic cell lineages and maintenance of β-cell function [52].  
Expression of PDX1 in pancreatic progenitors is central to induct proper pancreatic 
organogenesis, which is demonstrated by pancreas agenesis in case of homozygous 
gene loss-of-function in humans. Moreover, several heterozygous missense and 
frameshift mutations on human PDX1 gene lead to distinct diabetic phenotypes, 
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highlighting PDX1’s important role on adult pancreatic function. These diabetic 
phenotypes characterise MODY4, an early onset type of diabetes that comprehends 
different levels of hyperglycaemia, associated with dysregulation of glucose homeostasis 
that result from different degrees of PDX1 functional impairment [96]. The complex 
regulation of PDX1 is further demonstrated by phenotypes arising from mutations on 
regulatory elements. For instance, mice mutants display pancreatic agenesis upon 
deletion of conserved promoter regions [113]. Furthermore, cis-regulatory mutations and 
epigenetic alterations of PDX1 are also associated to the development of T2D [114]. The 
distinct consequences of PDX1 dysregulation highlight the worth of studying the 
transcriptional regulation of this locus. Therefore, the work presented in this thesis aims 
to uncover important cis-regulatory mechanisms that affect PDX1 expression in vivo and 
might impact on diabetes development. 
Zebrafish pdx1 shows slightly different functions comparing to its human ortholog, 
as demonstrated in loss-of-function pdx1 model. Homozygous pdx1 null mutation in 
zebrafish leads to endocrine dysfunction and diabetic traits; on the other hand, distinctly 
from human and mouse, pancreatic organogenesis still occurs [87, 93]. Therefore, 
progenitor and adult human PDX1 CREs might be studied in the context of transgenesis 
reporter assays. Additionally, adult human PDX1 CREs might be studied functionally, 
since loss-of-function of pdx1 does not generate a pancreatic agenesis phenotype. 
Overall, the PDX1 loci is the most adequate to reach the proposed objectives. 
 
2. PDX1 locus analysis 
1) Analysis of PDX1-linked SNP associated to T2D 
The T2D-associated polymorphism rs35369009 (chr13:28,490,510, 
GRCh37/hg19/Human listed in Table 3) is positioned in an intron of a long non-coding 
RNA (lncRNA) gene, PDX1-associated lncRNA upregulator of transcription (PLUT). This 
antisense lncRNA was shown to promote interaction between the PDX1 promoter and 
an upstream enhancer cluster, thus enhancing PDX1 transcription [115]. Analysis of 
rs35369009 SNP reveals co-localization with an H3K27ac peak detected in adult 
pancreatic islets (Figure 4). Additionally, the SNP co-localizes with H3K4me1 peaks 
detected in human embryonic stem cell line (h1-HESC; data from the ENCODE Project). 
According to Parker S.C and colleagues, rs35369009 is contained within a stretch 
enhancer [28]. Stretch enhancers are defined as enhancer regions that are extended for 
a length of 3 kilobases (kb) or more, often laying on locus regulatory regions and showing 
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tissue-specific activity [28]. Interestingly, this SNP was also reported to be located within 
an islet active enhancer in the study of Pasquali and colleagues (Figure 4; [7]). 
 
 
Figure 4. Epigenetic features characterising the T2D-associated rs35369009 SNP in the PDX1 
locus. The top three tracks indicate functional prediction of the region adjacent to the SNP. Chromatin 
classes described by Pasquali L., and colleagues show annotations of enhancers (in red) and promoters (in 
black) detected in adult human islets [7]. Chromatin states defined by Miguel-Escalada I., and colleagues 
2019 (Islet Regulome) include weak and strong enhancers (in light blue and orange, respectively) and active 
promoters (in red) [116]. The middle three indicate histones code analysis in human islets; the bottom tracks 
enhancer marks by ChIP-Seq in the correspondent cell lines. The SNP is vertically highlighted in cyan. The 
genomic coordinates are indicated at the top of the figure.  
 
We also have investigated in detail the in vivo binding of the five key TFs operating 
in human islets [7] and additional TFs involved in early pancreas development in human 
pancreas multipotent progenitor cells (MPC; [39]). Figure 5 (next) summarize this 
analysis, suggesting that there is no binding of PDX1 to its upstream region containing 
the SNP, while the other four key players could bind in that region, although presenting 
very low levels of binding. As there is no positive feedback by binding of PDX1 itself, it 
is worth to speculate that this region could be responsible for opening the locus at specific 
timepoints – in line with the onset of expression of the other factors, but not for sustaining 
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PDX1 transcription by a positive feedback loop mediated by PDX1 itself: FOXA2 and 
NKX2.2 are expressed earlier than PDX1 during development, whereas MAFB and 
NKX6.1 later. Thus, it could be possible that the activity of this putative regulatory 
element will be restricted to two distinct temporal stages.  
 
Moreover, TEAD1, known for regulating transcription of many genes in a context-
specific-manner, was found to bind this region very mildly, in pancreatic progenitor cells, 
again suggesting an early role of this sequence during pancreatic development [39]. 
Overlapping of rs35369009 with epigenetic marks for enhancer activity and with 
binding sites of key-pancreatic TFs suggests that the association of the human 
polymorphism with diabetes could be explained as a result of the disruption of normal 
transcriptional cis-regulatory networks. Because PDX1 has a central role on pancreatic 
development and adult function, it will be crucial to investigate whether the disruption of 
PDX1 regulatory mechanisms could be sufficient to cause a perturbation of glucose 
homeostasis and lead to other T2D-associated phenotypes. 
Figure 5. ChIP-Seq illustrates the in vivo binding of the indicated transcription factors in human islets 
(coloured tracks), as well as in progenitor cell lines (black tracks), around the T2D-associated rs35369009 
SNP in the PDX1 locus. The SNP is vertically highlighted in cyan. The genomic coordinates are indicated at 
the top of the graph. 
FCUP 
Study of human regulatory mutations associated with pancreatic diseases by humanizing the zebrafish genome. 
49 
 
 
 
2) Prediction of PDX1 CREs 
In order to identify PDX1 putative CREs, the locus was explored in the Islet 
Regulome Browser (GRCh37/hg19 /Human) (Figure 6). Through the analysis of long-
range interactions of the gene promoter sequence detected by pcHi-C, we were able to 
define putative limits of the PDX1 regulatory landscape, being restricted between the 
coordinates chr13:28,397,000-28,510,000 (GRCh37/hg19 /Human). After defining the 
putative genomic coordinates of the PDX1 regulatory landscape, a screening for PDX1 
putative CREs was conducted. Sequences enriched in H3K27ac modifications detected 
in human pancreatic islets suggest the presence of three putative enhancers (hereafter 
referred as en1, en2 and eSNP). While the putative enhancer sequence termed eSNP 
is contained within a region showing enrichment for H3K27ac but not H3K4me1, the 
selection of the sequence of interest was mainly based on the location of the T2D-
associated SNP, rs35369009. Sequences en1 and en2 were defined accordingly to 
overlap between regions showing enrichment in H3K27ac epigenetic mark and also 
interactions of the PDX1 promoter detected by pcHi-C. The genomic coordinates of the 
putative enhancers are presented in Table 5. 
Table 5. Putative enhancer sequences selected in PDX1 locus. 
Sequence Genomic coordinates (GRCh37/hg19) Putative enhancer length (bp) 
en1 PDX1 chr13:28413883-28415558 1676 
en2 PDX1 chr13:28442455-28443986 1532 
eSNP PDX1 chr13:28489417-28490575 1159 
 
Furthermore, we predicted the presence of insulators in the PDX1 regulatory 
landscape, using CTCF and cohesin ChIP-Seq tracks, as these proteins are associated 
to insulator functions, establishing barriers within adjacent genes landscapes, as well as 
modulating enhancer activity [20]. Three sequences were selected, two upstream the 
PDX1 coding sequence (named ins1 and ins2), and one region downstream (ins3; 
Figure 6). It will be interesting to understand whether these are the regions defining the 
TAD of PDX1, or whether they are acting within a bigger TAD to modulate PDX1 
transcription by modulating the activity of other enhancers. The genomic coordinates of 
the putative insulators are presented in Table 6. 
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Table 6. Putative insulator sequences selected in PDX1 locus. 
Sequence Genomic coordinates (GRCh37/hg19) Putative insulator length (bp) 
ins1 PDX1 chr13:28400284-28401759 1476 
ins2 PDX1 chr13:28403943-28404737 795 
ins3 PDX1 chr13:28503601-28504743 1143 
 
The putative CREs, both insulators and enhancers, overlap with open regions of 
chromatin detected by ATAC-Seq in human islets (Figure 6). The availability of these 
sequences is consistent with the requirement for those to be accessible to the binding of 
TFs. 
 
 
 
3. Validation of PDX1 CREs in zebrafish 
1) Subcloning of putative CREs sequences into entry vector 
The sequences selected as PDX1 putative CREs were amplified by PCR. To do so, 
primers flanking these sequences were designed, which are listed in Table 6 (see 
Materials and Methods, Table 3). PCR amplification was performed using as template 
Figure 6. Screening for putative CREs and defining the PDX1 landscape. On top of the picture, 
the scale is indicated; below, dashed rectangles highlight the selected putative CREs with respective names. 
The first track corresponds to ATAC-Seq data showing regions of open chromatin; the following three tracks 
shows genomic regions enriched in CTCF, cohesin and Mediator binding detected by ChIP-Seq; next two 
tracks show histone enrichment in H3K4me1 and H3K27ac epigenetic marks that define enhancer regions; 
below, there are presented annotations of putative regulatory elements; and finally, the last track shows 
chromatin interactions detected by pcHi-C, with a viewpoint in PDX1 promoter. All the data presented in the 
figure corresponds to assays performed in human pancreatic islets. At the bottom of the figure, genes are 
illustrated. 
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DNA, a PDX1 BAC containing the human genomic regions of interest or a sample of 
human genomic DNA (gDNA) (Figure 7 A and B, respectively). PCR reactions were run 
in a 1% (w/v) agarose gel and amplicons were confirmed to be the expected molecular 
weight (Figure 7 and 8). 
Putative CREs sequences were amplified first from the PDX1 BAC and then from 
gDNA from healthy patients for technical and biological reasons. First, it is easier to 
optimize a PCR employing single molecule as a BAC than a higher-complexity DNA 
sample as genomic DNA. More importantly, as the final aim of this thesis is to introduce 
A 
B 
Figure 7. Electrophoresis gel of PCR amplification of PDX1 putative CREs from (A) BAC DNA template 
and (B) gDNA template. Symbols "-" and "+" refer to PCR negative control (blank) and DNA-containing PCR 
mixes, respectively; while “L” represents the 1 kb ladder. The amplified regions are indicated on the top of 
the gel, while their correspondent size is depicted at the bottom. 
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a human PDX1 BAC into the zebrafish genome (see Chapter 4), it is required to evaluate 
the exact sequences situated in the PDX1 BAC, as they might carry mutations. 
Interestingly, the ins2 region was found to be amplified exclusively when using 
template from human gDNA (Figure 7), failing when using BAC DNA, even after 
optimization through a gradient of annealing temperatures between 54 and 60 °C (Figure 
8). Absence of PCR product derived from the BAC could be better explained by 
explained by the presence of a mutation, namely in the region where the primer pair was 
designed to anneal, thus impairing amplification of this putative CRE, or alternatively by 
a deletion. New primers should be designed spanning a larger sequence, flanking the 
selected region. Another possible explanation for the absence of PCR product when 
using the PDX1 BAC as template could be caused by the formation of DNA secondary 
structure due the sequence itself, which might be more stable in a single molecule as 
the BAC template, although this hypothesis is less likable since gDNA PCR product is 
obtained.  
 
 
Figure 8. Electrophoresis gel of PCR amplification of PDX1 putative CRE ins2 from gDNA and 
BAC templates. Symbols "-" and "+" refer to PCR negative control (blank) and DNA-containing PCR mixes, 
respectively; while “L” represents the 1 kb ladder. The annealing temperatures and the templates are 
indicated on the top of the gel, while the correspondent size is depicted at the bottom. 
 
After amplification of the PCR products, the amplicons were cloned into the entry 
vector pCR™8/GW/TOPO®. Success of cloning reactions was then confirmed by 
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restriction of extracted plasmids with EcoRI restriction enzyme. pCR™8/GW/TOPO® 
vector includes two EcoRI restriction sites flanking the gateway site (see Materials and 
Methods). Consequently, digestion of the vector containing the putative CREs cloned 
within should result in two linear DNA fragments, one with a size of 2817 bp (vector 
backbone) and the other with the size of the correspondent sequence contained. 
Digestion products were analysed in a 1% agarose gel and confirmed the successful 
cloning of each putative CRE into the entry vector (Figure 9). 
 
 
Figure 9. Representative electrophoresis gel of pCR™8/GW/TOPO® vector containing PDX1 putative 
CREs after digestion with EcoRI restriction enzyme. Each lane of the gel shows a 2817 bp band (vector 
backbone) and the band corresponding to the size of the cloned sequence. Symbol “L” represents the 1 kb 
ladder. 
 
(1) CREs sequences analysis derived from BAC and gDNA PCR 
amplification 
For each PDX1 putative CRE cloned into the entry vector pCR™8/GW/TOPO®, the 
presence of the correct sequence in the entry vector was further confirmed by Sanger-
sequencing. Sequencing results were analysed by alignment of reads with the most 
recent version of the human DNA available in UCSC Browser (GRCh37/hg19; Tables 4 
and 5). Sequencing results allowed the confirmation of correct cloning of PDX1 putative 
CREs in the entry vector and, importantly, alignment allowed to detect human variants 
in the cloned sequences, that were later tested as CREs.  
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The eSNP was amplified from the BAC and human gDNA. The gDNA sequencing 
results revealed three single nucleotide variants (SNVs) comparing to the reference 
sequence. One is described as a common polymorphism (that is, a SNP) (rs6491240), 
while the remaining two variants located at chr13:28,490,008 and chr13:28,490,511 
were not annotated in dbSNP database [117]. Furthermore, the sequence obtained from 
the BAC contains two SNPs, with the following genomic coordinates: chr13:28,490,214 
and chr13:28,490,288, which were both previously annotated in the dbSNP database as 
rs6491240 and rs2297317, respectively (Figure10) [117]. More importantly, the T2D-
associated SNP located in this region was not detected on the sequencing results 
obtained, both from BAC DNA and gDNA samples, being the ideal BAC clone to use for 
humanizing the zebrafish genome, as proposed in Chapter 4. 
Figure 10. Alignment of sequencing reads of eSNP cloned in pCR™8/GW/TOPO® with the human 
genome (GRCh37/hg19). Each box depicts regions where polymorphisms were detected; at the side 
genomic coordinates and the mutations are illustrated. When the mutations are described as common SNPs 
are shown together with the correspondent code (format ‘rs#’). Polymorphisms detected in sequences 
amplified both from the BAC DNA and gDNA templates are presented underlined. 
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Figure 11. Alignment of sequencing reads of en2 and en1 cloned in pCR™8/GW/TOPO® with the 
human genome (GRCh37/hg19). Each box depicts regions where polymorphisms were detected; at the side 
genomic coordinates and the mutations are illustrated. When the mutations are described as common SNPs 
are shown together with the correspondent code (format ‘rs#’). 
 
Alignment of reads from pCR™8/GW/TOPO® containing the putative enhancers 
en1 and en2, amplified using the PDX1 BAC as template DNA, confirmed the successful 
cloning of the desired sequences. In the case of en1, the amplified sequence from the 
BAC DNA led to identify three SNVs, two of them annotated in dbSNP database 
(rs9507964 and rs11149500; Figure 11). An extra variant, not annotated in the 
annotated in dbSNP database, was detected in the position chr13:28,414,387 
corresponds to a C>T nucleotide modification. Regarding the en2 sequence, two SNVs 
were identified, none of them described in dbSNP database (Figure11). 
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The sequence ins1 was amplified both from BAC DNA and human gDNA. On the 
sequence amplified from BAC DNA, two variants were detected: the first corresponds to 
a five-nucleotides deletion (ATAAA) and the second to a SNP (Figure 12). Both the 
ATAAA deletion and the single nucleotide transition A>G have been described in dbSNP 
database. Regarding human gDNA, ins1 sequence contains four SNVs comparing to the 
reference genome: three of those were already reported in dbSNP, while the nucleotide 
transition at position chr13:28,400,607 was not reported (Figure 12).  
Figure 12. Alignment of sequencing reads of ins1 cloned in pCR™8/GW/TOPO® with the human 
genome (GRCh37/hg19). Each box depicts regions where polymorphisms were detected; at the side 
genomic coordinates and the mutations are illustrated. When the mutations are described as common SNPs 
are shown together with the correspondent code (format ‘rs#’). Polymorphisms detected in sequences 
amplified both from the BAC DNA and gDNA templates are presented underlined. 
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Figure 13. Alignment of sequencing reads of en2 and en1 cloned in pCR™8/GW/TOPO® with the 
human genome (GRCh37/hg19). Each box depicts regions where polymorphisms were detected; at the side 
genomic coordinates and the mutations are illustrated. When the mutations are described as common SNPs 
are shown together with the correspondent code (format ‘rs#’). 
 
Alignment of reads from pCR™8/GW/TOPO® containing the putative insulator ins2 
amplified from gDNA allowed to detect four variants: three SNVs and one deletion of 22-
nucleotides. None of the SNVs is described in dbSNP database (Figure 13). 
Interestingly, the deletion of 22 nucleotides within the putative insulator has already been 
described in dbSNP. Moreover, the detection of this deletion along with the other three 
SNPs reinforces the hypothesis that amplification of ins2 from BAC DNA could indeed 
have been impaired due to presence of mutations in this template sequence. 
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Finaly, sequencing results obtained from the pCR™8/GW/TOPO® construct 
containing the putative insulator ins3 confirmed successful cloning of sequences 
amplified both from BAC DNA and gDNA. Alignment of reads with the reference genome 
led to detect two SNVs on the BAC ins3 sequence (Figure 14). Of these two, only one 
was reported in dbSNP database (rs956889293). In case of gDNA ins3 sequence, four 
SNVs were detected. Of those, only the most downstream variant is reported in dbSNP. 
Remarkably, despite unreported in the database, the variant detected at position 
chr13:28,503,684 was found to be included in ins3 sequences amplified from both DNAs. 
A summary of these results is presented in Table 7. Considering the size of each of 
the putative CREs (from 700 bp to 2 kb, approximately), overall no drastic sequence 
aberrations were detected. However, many variants are present in these sequences, 
some being already annotated in the SNP database as common SNPs, but some are 
not (referred as SNVs). A cautionary note must be highlighted regarding especially the 
second class of variants, since they are not described as common SNPs, opening the 
possibility of having deleterious consequences in CREs activity. Nevertheless, 
considering that most annotated SNPs derive from exome-sequencing, it is likely that the 
statistical significance in non-coding regions to define common SNPs are not so powerful 
yet. Moreover, there are many SNPs/mutations common between the two human PDX1 
sequences (BAC and gDNA; summarized in Table 7), indicating that these variants can 
Figure 14. Alignment of sequencing reads of ins3 cloned in pCR™8/GW/TOPO® with the human 
genome (GRCh37/hg19). Each box depicts regions where polymorphisms were detected; at the side 
genomic coordinates and the mutations are illustrated. When the mutations are described as common SNPs 
are shown together with the correspondent code (format ‘rs#’). Polymorphisms detected in sequences 
amplified both from the BAC DNA and gDNA templates are presented underlined. 
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indeed be more prevalent, although not annotated. Lastly, this characterisation at single 
nucleotide resolution will be very important when combining with in vivo CREs reporter 
assays, to determine if some of these variants might have an impact be the CRE activity. 
 
Table 7. Summary of mutations in the amplified indicated sequences, classified for the template used, 
either the PDX1-BAC or gDNA. For annotated SNPs, their reference is reported. Common mutations 
between the two templates are underlined. *Del stands for delCAGGTGCGG(C)5GCGCCCGG. 
 
 
 
Putative 
CREs 
BAC gDNA 
Polymorp
hism 
Genomic 
coordinates 
(GRCh37/hg19) 
dbSNP 
code 
Polymorp
hism 
Genomic 
coordinates 
(GRCh37/hg19) 
dbSNP 
code 
eSNP 
   C592T chr13:28,490,008 – 
C798T chr13:28,490,214 
rs649124
0 
C798T chr13:28,490,214 
rs649124
0 
G872A chr13:28,490,288 
rs229731
7 
C1094T chr13:28,490,511 – 
en2 
C308A chr13:28,442,762 – 
 
C1189A chr13:28,443,987 – 
en1 
C505T chr13:28,414,387 – 
 C836T chr13:28,414,718 
rs950796
4 
A1373G chr13:28,415,255 
rs111495
00 
ins1 
   C201A chr13:28,400,484 
rs955140
3 
   T324C chr13:28,400,607 – 
delATAA
A 
chr13:28400655-
28400659 
rs600134
04 
delATAA
A 
chr13:28400655-
28400659 
rs600134
04 
A1431G chr13:28,401,714 
rs189194
9 
A1431G chr13:28,401,714 
rs189194
9 
ins2  
A167G chr13:28,404,109 – 
Del* 
chr13:28,404,283-
28,404,304 
rs540139
919 
C504T chr13:28,404,446 – 
A769G chr13:28,404,711 – 
ins3 
A84G chr13:28,503,684 – A84G chr13:28,503,684 – 
T610C chr13:28,504,210 
rs956889
293 
A916G chr13:28,504,516 – 
   T933C chr13:28,504,533 – 
   T968C chr13:28,504,568 
rs148227
7396 
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2) Recombination of putative CREs sequences into destination vector 
The sequences cloned pCR™8/GW/TOPO® were further transferred into 
destination vectors using gateway recombination, which were then used to functionally 
evaluate the role of these human sequences as CREs. The destination vectors are: (1) 
the Z48 vector for putative enhancers and (2) the insulator test vector for putative 
insulators. 
 
(1) Enhancer test vector 
 
 
Figure 15. Representative electrophoresis gel of Z48 vector containing PDX1 putative CREs after 
digestion with EcoRI restriction enzyme. Symbol “L” represents the 1 kb ladder. The first lane shows the 
digestion pattern of the Z48 empty vector. The other lanes illustrate specific digestion pattern of successfully 
cloned regions into Z48.  
 
Putative enhancers were recombined into the Z48 transposable element. 
Successful recombination of putative enhancer sequences was tested by digestion of 
extracted plasmids with EcoRI restriction enzyme. Similarly to pCR™8/GW/TOPO®, Z48 
vector contains two EcoRI restriction sites flanking the cloning site. Additionally, the 
vector contains one more restriction site placed in-between the GFP cassette and Z48 
enhancer. Consequently, digestion of the vector containing the putative CREs cloned 
within should result in three DNA fragments, two with sizes of 4279 bp and 1835 bp 
(vector backbone) and the third with the size of the cloned putative CRE. Digestion 
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products were analysed in a 1% agarose gel and confirmed the successful cloning of 
each putative enhancer into Z48 vector (Figure 15). 
 
(2) Insulator test vector 
 
Figure 16. Representative electrophoresis gel of insulator test vector containing PDX1 putative CREs 
after digestion with EcoRI restriction enzyme. Symbol “L” represents the 1 kb ladder. The second lane shows 
the empty vector after digestion, resulting in four bands. The other lanes illustrate specific digestion pattern 
of successfully cloned regions into insulator test vector. 
 
Putative insulators were recombined into the insulator test vector and successful 
recombination of putative insulator sequences was tested by EcoRI digestion of 
plasmids. The insulator test vector contains four EcoRI recognition sequences, two of 
them flanking the vector cloning site. Restriction of the empty vector (without a cloned 
sequence) results in multiple bands, presented in the first lane of the electrophoresis gel 
(Figure 16) – specific size of bands is not shown since the full sequence of insulator test 
vector was not available. Alternatively, the successful cloning was confirmed by 
difference in the digestion pattern from the empty vector. Additionally, the size of the 
bands obtained upon digestion was approximately calculated from the gel and their 
resulting sum confirmed the insertion of the expected sequences (Figure 16). 
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3) Transgenesis assays to test CREs activity 
(1) Test of PDX1 putative enhancers   
In order to test the function of the human sequences selected as pancreatic 
enhancers, each Z48 vector containing putative PDX1 enhancers was injected in one-
cell stage zebrafish embryos along with Tol2 mRNA [106]. Because PDX1 is expressed 
in endocrine differentiated cells and pancreas progenitor cells [52], we searched for ways 
to label these different zebrafish cell types. To help locate the zebrafish pancreas, we 
took advantage of a Somatostatin-mCherry (sst-mCherry) zebrafish reporter line, where 
the sst2 promoter drives the expression of the mCherry reporter gene in δ-cells since 17 
hpf [62], therefore consistently indicating the endocrine pancreas domain. Moreover, and 
because PDX1 is also expressed in the pancreatic progenitor domain, we labelled 
pancreatic progenitor cells using an anti-Nkx6.1 antibody [118]. In this experiment, we 
choose the 36 hpf time point since it is possible to detect differentiated endocrine cells 
and pancreas progenitor cells. A positive PDX1 CRE in this pancreatic enhancer reporter 
assay is therefore expected to drive GFP expression either within the sst-mCherry 
domain or the Nkx6.1 pancreatic progenitor domain. 
 
After microinjection of the Z48 vector, the Z48 enhancer triggers GFP expression in 
the midbrain of 24hpf zebrafish embryos, as illustrated in Figure 17, serving as an 
internal positive control for transgenesis (Figure 18). After selection of embryos that 
show expression of GFP in the midbrain, expression of GFP in the differentiated or 
progenitor domains is then assayed, using confocal microscopy and the 
abovementioned reporters. 
Figure 17. Representative confocal image of GFP expression in midbrain of a zebrafish embryo 
efficiently microinjected with a Z48 transposable element along with Tol2 mRNA. The dashed white line 
represents zebrafish midbrain. Leica confocal SP5II; zoom 1x; magnification 40x. 
FCUP 
Study of human regulatory mutations associated with pancreatic diseases by humanizing the zebrafish genome. 
63 
 
 
 
 
In this assay, the Z48 vector without a recombined CRE (empty Z48) was injected 
as a negative control. Out of fifteen embryos microinjected with the empty Z48 vector, 
one showed GFP expression in endocrine domain (Figure 19 A and B). The GFP 
expression detected in the pancreas of this embryo might be explained by a 
phenomenon called “position effect” [15]. Tol2 transposase integrations occur randomly 
in the genome, with some of those being nearby pancreatic enhancers, having the 
potential to induce the expression of GFP in pancreatic cells. This negative control 
anticipates that the threshold of noise for this assay is one out of fifteen (6,7%) GFP 
positive embryos. However, the number of analysed embryos is yet small and should be 
increased in future experiments. 
Figure 18. Scheme of the Z48 vector and GFP expression driven in zebrafish. (A) Empty Z48 vector. 
GFP expression is driven in the midbrain due to interaction of the Z48 midbrain enhancer with the minimal 
promoter upstream the reporter gene. (B) Z48 vector containing a cloned pancreatic enhancer upstream the 
minimal promoter. GFP expression is driven in zebrafish midbrain and pancreas, due to interaction of the 
Z48 and the pancreatic enhancer, respectively, with the minimal promoter. 
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To determine the sensibility of this assay to detect endocrine enhancers, a 
sequence previously validated as a pancreatic enhancer through luciferase reporter 
assays performed in a mice β-cell line, was used as positive control [7]. As preliminary 
data, out of eight embryos analysed, two showed GFP expression in the endocrine 
domain (25%; Figure 20). The number of analysed embryos is yet small and should be 
increased in future experiments. 
 
 
Figure 19. Representative confocal images of the pancreatic domain of embryos at 36 hpf injected 
with empty Z48 vector. Red fluorescence represents sst-expressing cells from the transgenic line 
tg(sst:mCherry). (A) Representative image of GFP expression in the endocrine domain. (B) Representative 
image of absence of GFP expression in the pancreatic domain. Leica confocal SP5II; zoom 2,91x; 
magnification 40x. 
Figure 20. Representative confocal image of the pancreatic domain of embryos at 36 hpf injected with 
the Z48 vector containing a previously established enhancer. Red fluorescence represents the endocrine 
domain (sst-expressing cells), which was found to co-localize with GFP expression. Leica confocal SP5II; 
zoom 2,91x; magnification 40x. 
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Regarding the PDX1 putative enhancers, three loci were tested (eSNP, en1 and 
en2; Figure 6). For the eSNP locus, two sequences were amplified, one from the 
respective BAC DNA (eSNP BAC; BAC clone CH17-423D7) and another from genomic 
DNA (eSNP gDNA).  For sequence eSNP gDNA, one out of seventeen embryos (5,9%) 
showed GFP expression in the pancreatic progenitor domain, and none in the pancreatic 
endocrine domain (Figure 21). For sequences en1 BAC (N=13) and en2 BAC (N=12), 
none of the analysed embryos showed GFP expression in the pancreatic endocrine or 
progenitor domain. Representative confocal images referring to the analysis of each 
sequence are shown in Figure 21. 
Overall, the data provided through this assay was not able to validate or exclude the 
activity of the three analysed loci as enhancers, from the PDX1 genomic landscape. The 
positive control showed a predicted tendency for having an increased number of 
embryos with GFP expression in the pancreatic endocrine domain, when comparing with 
the negative control (25% vs 6,7%). However, because the number of analysed embryos 
is yet limited, this difference is not statistically significant (P-value > 0,05 in unpaired t-
test with Welch's correction; P-value = 0,3255). In future experiments an increased 
number of embryos must be analysed. Additionally, it is possible that the absence of 
GFP expression detected in the pancreatic domain of the majority of the zebrafish 
embryos analysed in different experimental conditions outcomes from low transgenesis 
efficiency. An inefficient integration of the Z48 transposable element in the zebrafish 
genome might lead to a decrease in the expression of the GFP reporter contained within, 
therefore being insufficient to detect that expression in the pancreatic domain. This can 
be improved by using quantitative assays to determine expression of GFP in the midbrain 
to evaluate the efficiency of transgenesis, as an alternative to the qualitative appreciation 
currently performed. Finally, we could also hypothesize that the sequences in test are 
unable to enhance GFP expression in the chosen timepoint. That is, PDX1 enhancers 
might not be active at 36 hpf in zebrafish, becoming active at a later developmental stage, 
in mature pancreatic endocrine cells.  
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Figure 21. Representative confocal images of the pancreatic domain of embryos at 36 hpf injected 
with: eSNP amplified from BAC DNA (eSNP BAC) and from human gDNA (eSNP gDNA); en2 and en1 
amplified from BAC DNA (en2 BAC and en1 BAC). Red fluorescence represents sst-expressing cells from 
the transgenic line tg(sst:mCherry). Yellow arrows are pointed to GFP-positive cells. Leica confocal SP5II; 
zoom 2,91x; magnification 40x. 
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(2) Test of PDX1 putative insulators   
In order to test whether the human sequences selected and shown in Table 5 can 
function as insulators, each insulator test vector containing putative PDX1 insulators was 
injected in one-cell stage zebrafish embryos along with Tol2 mRNA [106]. The insulator 
test vector contains a tissue-specific promoter – Cardiac Actin promoter – that drives 
expression of a GFP reporter in zebrafish muscle cells upon microinjection. Upstream 
the muscle-specific promoter the transposon contains the Z48 enhancer, which drives 
GFP expression in the zebrafish midbrain (Figure 22) [15]. Additionally, the vector holds 
a gateway site where sequences can be easily cloned, between Z48 enhancer and the 
vector promoter. 
 
 
For these assays, zebrafish embryos were injected with the different insulator test 
vector containing the respective putative insulators to test, and the empty insulator vector 
(not containing a cloned insulator) was employed as a negative control in this 
transgenesis assay. Embryos were documented at 24 hpf (Figures 23 and 24) and mean 
of GFP intensity was quantified by imaging analysis in the midbrain and somites. 
Because an insulator should impair the expression of GFP detected in the midbrain, 
while the expression of GFP in somites should be maintained, to access the insulator 
activity of the tested sequences, the ratio of the mean GFP intensity in the somites 
divided by the midbrain was calculated, and values were compared to the negative 
control (Figure 24). As positive control, an insulator vector containing the well-known 
5’HS4 chicken β-globin insulator was employed in the reporter assay. The 5’HS4 
Figure 22. Scheme of the insulator test vector and GFP expression driven in zebrafish. (A) Empty 
insulator test vector. GFP expression is driven in zebrafish somites due tissue-specificity driven by the 
Cardiac Actin promoter upstream the reporter gene, and in midbrain due to interaction of the Z48 enhancer 
(midbrain enhancer) with the promoter. (B) Insulator test vector containing a cloned insulator upstream the 
promoter. GFP expression is driven in zebrafish somites, while GFP expression in midbrain is comparatively 
decreased due to blocking of the interaction between Z48 enhancer and the promoter. Adapted from Bessa, 
J. et al. (2009). 
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insulator was previously tested in zebrafish [15, 119]. Analysis of the values obtained for 
the condition used as positive control reveals that all the tested sequences show 
insulator activity.  
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Figure 23. Representative 
images of 24 hpf zebrafish embryos 
injected with: empty insulator 
vector; the insulator vector 
containing 5’HS4 insulator; and the 
insulator vector containing ins1 
(from BAC and gDNA), ins2 (gDNA) 
and ins3 (BAC and gDNA). Images 
acquired in stereomicroscope Leica 
M205, zoom 5x. 
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The sequence ins1 showed significant increase of GFP ratio between muscle and 
midbrain (Figure 23 and 24), compared to the negative control, showing its ability to 
block the interaction of the Z48 enhancer and the Cardiac Actin promoter. Of note, the 
sequence amplified from human gDNA showed higher insulator activity than the one 
amplified from BAC DNA. The function of this sequence as an insulator CRE is 
concordant with the bioinformatic data used in the prediction of PDX1 putative CREs, 
which shows enrichment of both CTCF and cohesin binding. 
The sequence ins2 amplified from human gDNA was also shown to be able to block 
interaction of the Z48 enhancer with promoter, which led to low GFP expression levels 
in midbrain of zebrafish. Similarly to ins1, the validation of this sequence as an insulator 
also corroborates the selection criteria for insulators explained in Chapter 1 (Results). 
From the Hi-C data, both insulator sequences are the long-range chromatin interaction 
more distant from the promoter, thus these results confirm our hypothesis that these two 
sequences might indeed define the border of PDX1 TAD.  
Regarding ins3 region, both sequences amplified from human gDNA and BAC DNA 
were validated as insulators, with a tendency of the first to stronger block the Z48 
enhancing action, but not significantly. According to the bioinformatic data used to predict 
PDX1 putative CREs, the genomic region containing this sequence is enriched in CTCF-
binding, although it is not clearly enriched in binding of the cohesin complex, nor is 
located in a clearly open region of chromatin detected by ATAC-Seq performed in 
pancreatic islets. Thus, we can hypothesize that the major contribution of ins3 to function 
as insulator is the CTCF binding. 
Altogether, these experimental evidences validated all three selected regions as 
insulators, using an in vivo reporter assay. Next, we aim to investigate the function of 
these putative CRE in regulating PDX1 expression at transcriptional level at early 
developmental stages or in adulthood. An interesting aspect will be to dissect whether 
these CRE are involved in PDX1 function of pancreas lineage commitment or in mature 
β-cells. 
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Besides validating the sequences in test as insulators, our results show differential 
levels of insulator activity for sequences amplified from BAC or gDNA DNA. Since we 
detected variants that differ among the same sequence but amplified from different 
templates, it is reasonable to hypothesize that the SNVs detected by sequencing are 
correlated with the activity levels detected. For instance, the statistically significant 
difference observed between ins1 sequences suggest that SNVs found in the BAC 
induce a decrease in the ability of that sequence to block enhancer activity. Therefore, it 
would be interesting to evaluate if the SNVs identified are responsible to modulate the 
insulator function in the PDX1 genomic context.  
Moreover, the chicken insulator 5’HS4 showed weaker insulator activity in this assay 
than any of the human sequences tested. The high number of zebrafish individuals 
injected with the vector containing 5’HS4 analysed in this assay (N=35) provides 
robustness to our data.  
Figure 24. Graphic referring to the ratio between GFP intensity measured in zebrafish somites and in midbrain 
for each condition tested. “NC” and “PC” refer to negative (Empty vector) and positive control (Insulator 5’HS4), 
respectively. Statistical analysis was performed with an unpaired T-test with Welch's correction relative to NC. All 
experimental conditions are statistically significant when comparing to the NC, showing associated P values < 0,05. 
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4. Humanization of the zebrafish genome 
Besides exploring the potential of individual non-coding sequences contained in 
PDX1 locus as CREs, we have also explored the possibility to study CREs within their 
original genomic context. Broad cis-regulation analysis was approached through 
manipulation of human BACs containing the selected regulatory landscape. This last 
chapter will describe the initial steps of generating a humanized PDX1 zebrafish line, 
inserting a BACs carrying the human PDX1 regulatory landscape into the zebrafish 
genome [56]. 
 
1) BAC clone extraction and diagnostic 
The BAC containing human PDX1 regulatory landscape was selected because it 
spans a long region containing the PDX1 gene, thus ensuring the whole PDX1 landscape 
will be present. 
First, DNA integrity of PDX1 BAC was validated through electrophoresis analysis. 
High-weight DNA molecules (as BACs) require particular manipulation to avoid DNA 
shredding: after extraction the PDX1 BAC needs to be transferred into another bacteria 
strain, therefore is crucial that the integrity of the circular molecule is maintained. DNA 
integrity was confirmed by run the PDX1 BAC plasmid in a 0.8% agarose gel, which 
reveals the presence of high-weight molecule, in a single band, likely representing the 
supercoiled structures and others, still located in the pocket of the well. Importantly, no 
DNA smear as sign of DNA degradation was observed (Figure 25). 
Figure 25. Diagnostic analysis of PDX1 BAC DNA extraction. Electrophoresis of PDX1 BAC 
plasmid (approximately 200 ng) in 1% (w/v) agarose gel. Symbol “L” represents the Lambda 
DNA/HindIII Marker and correspondent band sizes. 
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Further analysis of PDX1 BAC was performed to confirm presence of the correct 
human genomic sequences selected as putative CREs. The selected sequences were 
amplified by PCR, followed by run of PCR products on agarose gel. A representative 
figure of the PCR products is shown in results presented above (see Results; Figure 
7A). Therefore, PDX1 BAC could be used to reliably represent the human PDX1 locus.  
 
2) PDX1 BAC recombineering 
To achieve highly efficient transgenesis in zebrafish, PDX1 BAC was manipulated 
through BAC recombineering. This technique was performed to prepare the BAC DNA 
so it could be more efficiently integrated in the zebrafish genome upon microinjection – 
through insertion of Tol2 transposase recognition sequences [106]. BAC recombineering 
requires bacterial electroporation of the BAC into a specialized bacterial strain, 
engineered to express protein for recombination based on homology arms (deriving from 
the lambda phage), amplification of a linear DNA fragment containing Tol2 arms, 
followed by its electroporation, and induction of bacterial recombinase functions. 
 
(1) BAC electroporation 
To perform BAC recombineering, we used the recombinogenic bacteria SW102, 
modified from strain E. coli DH10B. Thus, after extraction and purification of plasmid 
DNA, the PDX1 BAC was electroporated in E. coli SW102.  
Electroporation of PDX1 BAC into E. coli SW102 required several optimizations of 
the protocol followed [56]. Fresh electrocompetent cells were prepared immediately 
before electroporation every time, since the efficiency of this type of bacterial 
transformation is significantly decreased upon cell frost. Aliquots of electrocompetent 
cells were incubated with purified plasmid DNA (PDX1 BAC) and placed in pre-chilled 
electroporation cuvettes. Different BAC DNA concentrations were tested, namely 200 ng 
and 1 ug. The two DNA concentrations were tested in different electroporation 
conditions, including voltages of 1,2 and 1,8 kV, with constancy of electric capacitance 
and resistance conditions to 25 mF and 200 Ω, respectively. In every batch of competent 
bacteria and following BAC electroporation experiments, known concentrations of a 
supercoiled plasmid were electroporated in parallel, reflecting the conditions under test 
in each BAC electroporation, namely adjusting volumes. This positive control was used 
to calculate the competence efficiency of every freshly prepared batch of bacteria. 
FCUP 
Study of human regulatory mutations associated with pancreatic diseases by humanizing the zebrafish genome. 
74 
 
 
 
According to the positive control, higher transformation efficiency of E. coli SW102 
cells was achieved through use of a voltage of 1,2 kV during electroporation. The 
transformation efficiency was approximately 9x107 Colony Forming Units (CFU)/ug of 
DNA, comparing to 1,26x107 CFU/ug when using 1,8 kV. Under the same electroporation 
conditions, three replicate electroporation experiments with 200 ng and 1 ug of BAC DNA 
were conducted, resulting in growth of one single colony in one of the three selective 
agar plates obtained after plating of electroporated cells, for each DNA concentration.  
Single colonies grown in selective medium were tested for PDX1 BAC incorporation 
in two consecutive steps. First, double antibiotic selection was performed to confirm 
resistance to chloramphenicol (resistance provided by the PDX1 BAC plasmid) and to 
tetracycline (resistance provided by the strain E. coli SW102), illustrated in Figure 26. 
The first electroporation aimed to insert the BAC into the recombinase-competent 
SW102 strain, maintaining the BAC of interest in single colonies.  
 
 
(2) Amplification of Tol2 cassette 
To allow efficient BAC transgenesis in zebrafish, the PDX1 BAC was modified 
through insertion of Tol2 recognition sequences – the Tol2 cassette.  
Figure 26. Experimental setup for recombineering of the PDX1 BAC. The bacterial strain 
E. coli SW102 was plated to select cell clones, represented as single colonies containing resistance 
to tetracycline (TETR, in blue). Then, the PDX1 BAC was electroporated into that strain and single 
colonies of E. coli SW102 containing the BAC were selected by gaining of chloramphenicol resistance 
(CLR, in purple). Finally, the Tol2 cassette was electroporated into cells previously selected from 
single colonies of E. coli SW102:BAC. Colonies containing successful recombined BAC molecules 
were selected by gaining of ampicillin resistance (AMPR, in black). 
FCUP 
Study of human regulatory mutations associated with pancreatic diseases by humanizing the zebrafish genome. 
75 
 
 
 
Amplification of the Tol2 cassette was performed using pCR8GW-iTol2 plasmid as 
template in a PCR reaction. This vector contains two inverted sequences sufficient for 
Tol2 transposase recognition, flanking an ampicillin resistance gene, hereafter referred 
as Tol2 cassette. Its PCR-based amplification for the recombineering protocol required 
the design of primers annealing to the edge of the Tol2 cassette with as overhangs 50 
bps homology to the targeted site on the backbone of the BAC. The Tol2 cassette was 
amplified with a proofreading enzyme, followed by electrophoresis of PCR products 
shown in Figure 27. Upon confirmation of PCR amplification of the Tol2 cassette, the 
template DNA plasmid used for amplification was digested with DpnI restriction enzyme. 
This enzyme belongs to a group of methylation-specific restriction endonucleases, that 
specifically digests plasmid DNA, because it is methylated. On the contrary, the PCR 
product is demethylated, therefore will not be digested [120]. Complete digestion of 
template pCR8GW-iTol2 plasmid was ensured to inhibit arising of false-positive colonies 
in the BAC recombineering step performed hereafter, deriving from not digested plasmid 
used as template in the PCR reaction. Preparation of the Tol2 cassette for 
electroporation in E. coli SW102 was concluded with a DNA purification step followed 
elution in sterile water, because of the downstream applications: in fact, salt containing 
buffer could impair if not prevent electroporation. 
 
  
Figure 27. Electrophoresis gel of PCR amplification of Tol2 cassette from pCR8GW-iTol2 
plasmid. Symbol "-" refers to PCR negative control (blank), while “L” represents the 1 kb ladder. PCR 
amplifcation was performed testing two alternative annealing temperatures, 58 and 60 °C. The 
amplified cassette name is indicated on the top of the gel, while its correspondent size (Tol2 cassette 
flanked by 50 bp homology arms) is depicted at the bottom. 
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(3) BAC recombineering of Tol2 cassette 
The Tol2 cassette was electroporated in fresh prepared electrocompetent E. coli 
SW102:BAC cells, selected in the previous experimental step (Figure 27). During the 
preparation of electrocompetent cells, recombinase functions of the bacterial strain were 
inducted by heat-shock, immediately after cell growth until desirable density. Aliquots of 
electrocompetent cells were incubated with the three different amounts of purified Tol2 
cassette – 3,5 ng, 140 ng and 750 ng. Each DNA concentration was electroporated in 
duplicate. Electroporation shock was conducted in constant conditions, formerly 
associated to higher transformation efficiency during BAC electroporation – 1,2 kV of 
voltage, 25 mF of electric capacitance and 200 Ω of resistance. 
Insertion of the Tol2 cassette on the backbone of the BAC was achieved for the 
three concentrations of Tol2 tested in each of the voltages, along cell recovery and 
bacterial growth in unselective medium for 2 hours. SW102:BAC cells were then plated 
in medium containing antibiotic. Double antibiotic selection was performed with ampicillin 
(antibiotic resistance provided by the Tol2 cassette) and chloramphenicol (resistance 
provided by the PDX1 BAC). In this experimental setting, serial dilution of cells used in 
the positive control revealed a transformation efficiency of around 8,7x107. Cells 
electroporated with different amounts of the Tol2 cassette were platted separately. A 
total of 32 single colonies grew on selective medium, of which 19 colonies resulted from 
the electroporation of 140 ng of Tol2 cassette. 
Single colonies grown in selective medium were further tested for successful 
incorporation of the Tol2 cassette on PDX1 BAC through colony PCR and antibiotic 
resistance. This selection step, discussed in the following chapter, was particularly 
crucial due to the possibility of emergence of false-positive colonies. 
 
(4) Selection and preparation of BAC-Tol2 construct 
The selection of E. coli SW102 cells containing the BAC-Tol2 construct 
(SW102:BAC-Tol2) was performed by two methods: colony PCR and antibiotic selection. 
First, single colonies were tested for presence of the BAC-Tol2 construct by colony 
PCR. Two PCR amplifications were conducted through use of two pairs of primers – on 
one hand, we tested the insertion of a DNA sequence on the attB1 site contained in the 
backbone of the BAC (the target site of recombineering); on the other hand, we tested 
the insertion of our sequence of interest in the attB1 site, using a specific primer 
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complementary to the ampicillin resistance gene contained in the Tol2 cassette. The 
location of the primers designed is depicted in Figure 28. 
 
Results of the colony PCR performed with primers a and b were analysed by 
electrophoresis in agarose gel (Figure 29 A). As these primers were designed flanking 
the recombineering target site, amplification from a BAC construct without the Tol2 
cassette results a small DNA fragment of 148 bp, correspondent to the backbone of the 
non-recombined plasmid. Amplification from single colonies .1 and .2 resulted in two 
bands of low molecular weight of high intensity, revealing the presence of non-
recombined BAC molecules. The higher molecular weight bands shown in the following 
gel lanes (colonies .3-.5 and .7) reveal the presence of recombined BAC molecules, 
which contain the 1416 bp Tol2 cassette in the former attB1 site. Furthermore, the same 
high molecular weight band is also present in the lanes of colonies .1 and .2, although 
fainter than the ones obtained from other colonies. These results indicate that the single 
colonies under test contain different BAC molecules, recombined and non-recombined. 
Further selection was also performed considering that colonies .3-.5 and .7 present a 
higher proportion of recombined BAC molecules than colonies .1 and .2, interpreted by 
the amount of DNA amplified of each size. 
Colony PCR results obtained with primers c and b are shown in Figure 29 B. This 
PCR strategy retrieved more specificity in the BAC-Tol2 construct selection, since PCR 
products were specifically amplified from recombined BAC molecules. Results allowed 
to confirm that all SW102:BAC-Tol2 colonies tested indeed contain recombined BAC 
molecules.  
Figure 28. Scheme of the of PDX1 BAC-Tol2 construct and primers used in selection of E. coli 
SW102 cells containing the BAC-Tol2 construct by colony PCR. The two pairs of primers employed 
were a+b and c+b, which location is represented in the figure. 
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Moreover, selection of E. coli SW102:BAC-Tol2 colonies was complemented by an 
examination of antibiotic resistance. This strategy was relevant not only to confirm 
presence recombined BAC molecules inside E. coli SW102 bacteria, but also to detect 
the growth of false-positive colonies upon electroporation of the Tol2 cassette. In the end 
B 
Figure 29. Electrophoresis gel of PCR amplification of the target site of recombineering 
on the PDX1 BAC from E. coli SW102:BAC-Tol2 single colonies. The single colonies are 
indicated on the top of the gel. Symbol "-" refers to PCR negative control (blank), while “L” 
represents the 1 kb ladder. (A) Colony PCR products obtained with primers a and b, flanking 
the recombineering target site. Amplification from a non-recombined BAC molecule results a 
DNA fragment of 148 bp (backbone of the non-recombined plasmid), while amplification from 
a recombined BAC molecule results in a DNA fragment of 1539 bp. (B) Colony PCR products 
obtained with primers c and b, designed to amplify part of the Tol2 cassette inserted in a BAC 
molecule. Amplification of a single band corresponding to the junction between the Tol2 
cassette and a downstream sequence of the recombineering target site allows to detected 
successful recombineering. Size of the amplified sequence is depicted at the bottom. 
A 
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of the Tol2 recombineering protocol, three different DNA combinations can be contained 
in the cells grown on selective plates containing ampicillin and chloramphenicol. One is 
the desired recombined BAC molecule, comprising the resistance genes for both 
antibiotics in its backbone due to successful recombineering of the Tol2 cassette; other 
is the non-recombined BAC molecule, only conferring resistance to chloramphenicol; 
finally, the pCR8GW-iTol2 plasmid used as template for amplification of the Tol2 cassette 
could also be contained within these cells, conferring resistance to ampicillin. As 
mentioned above, complete digestion of pCR8GW-iTol2 plasmid from the PCR reaction 
by DpnI restriction enzyme was required in order to prevent growth of false-positive 
colonies. Even though the restriction reaction was set up accordingly to the 
recommended protocol, we could not ensure a 100 % effective restriction a priori. Thus, 
electroporation of a DNA sample containing the Tol2 cassette along with a small portion 
of pCR8GW-iTol2 plasmid would be sufficient to allow the growth of E. coli SW102 cells 
on LB-chloramphenicol-ampicillin plates. These false-positive colonies containing both 
non-recombined BAC molecules and pCR8GW-iTol2 plasmid should then be discarded. 
To do so, E. coli SW102:BAC-Tol2 colonies were streaked in LB-spectinomycin plates – 
additional antibiotic resistance cassette specific to this plasmid. Streak of the 32 single 
colonies grown upon electroporation in selective plates containing spectinomycin 
allowed to identify one false-positive. From the 31 colonies left, maintenance of the PDX1 
BAC on the correct bacterial strain was ensured by streaking in double selective agar 
plates containing, chloramphenicol and ampicillin. Single colonies grown on those plates 
were then used to extract the PDX1 BAC-Tol2 construct.  
  
3) Humanizing the zebrafish genome: PDX1 BAC transgenesis 
(5) pdx1 zebrafish mutant line 
As part of this thesis, a zebrafish mutant line for the pdx1 locus was reared in the 
animal facility - pdx1sa280/sa280. Professor Robin A. Kimmel and colleagues, who described 
this zebrafish mutant line generated by the Zebrafish Mutation Project, provided us with 
offspring of an incross between two heterozygous animals for the pdx1 mutation [93].  
The zebrafish pdx1sa280/sa280 line is characterised by a mutant allele containing a 
premature stop at codon (Y37X), located within the N-terminal protein transactivation 
domain. Differently from humans, zebrafish embryos containing the null mutation sa280 
on the pdx1 locus in the homozygous state reach adulthood, developing a pancreas. 
However, the mutants show decreased viability and a specific pancreatic phenotype, 
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characterised by reduced number of β-cells, low levels of insulin and perturbed 
differentiation of acinar cells. Furthermore, zebrafish pdx1 mutants respond to drug 
treatment used in human diabetic patients, which highlights its potential use as a genetic 
model of diabetes [93]. 
The establishment of the zebrafish pdx1 mutant line was conducted in order to test 
the rescue of loss-of-function upon transgenesis with the PDX1 BAC. We aim to 
determine whether the human PDX1 gene and its corresponding regulatory landscape 
can rescue the loss-of-function of its zebrafish ortholog. Thus, the human PDX1 BAC will 
be used to perform transgenesis in a pdx1 null background, provided by this zebrafish 
mutant line. If the rescue is feasible, this will be an excellent model to study the 
phenotypic consequences of non-coding regulatory mutations in the human genomic 
landscape of PDX1.  
The offspring of heterozygous pdx1 zebrafish mutants was raised until sexual 
maturity, so they could be genotyped for the mutation. Each animal was genotyped 
through outcross with a zebrafish WT line and DNA extraction from embryos. Upon PCR 
amplification of the zebrafish pdx1 locus, a digestion reaction with DraI restriction 
enzyme was performed (Figure 30 A). The rationale of this genotyping strategy lies in 
the fact that the null mutation contained in the pdx1 locus of the mutants creates a 
restriction DraI site, which is absent in non-mutated pdx1 alleles. Thus, after DraI 
digestion and electrophoresis, DNA extracted from embryos containing the mutant allele 
is detected by the emergence of a lower molecular weight DNA band, correspondent to 
a DNA fragment of 334 bp (right side of Figure 30 A). Lanes 1 to 4 refers to DNA 
extracted from batches of embryos holding the pdx1 mutant allele, which allows to 
identify progenitors as pdx1 mutants. Figure 30 B shows the difference at the sequence 
level among WT and pdx1 mutants, and corresponding DraI restriction site.  
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(6) BAC microinjection and toxicity evaluation 
The PDX1 BAC-Tol2 construct was used to injected one-cell stage zebrafish 
embryos. In this first approach, microinjection was performed in wt embryos to determine 
the range of BAC DNA amount in which we detect efficiency of transgenesis without 
compromising animal vitality. Since microinjection in zebrafish embryos is often 
performed with vectors of much smaller size than a BAC, we aimed to assess whether 
the amount of DNA injected should reflect the size of the transposon that will be 
integrated in the zebrafish genome. 
Figure 30. Genotyping of zebrafish pdx1 mutants. (A) Electrophoresis gel of 
PCR amplification of pdx1 locus from DNA extracted from batches of 8 zebrafish 
embryos (left side, “Before DraI digestion”) and the same PCR product upon 
digestion with DraI restriction enzyme (right side, “DraI digested”). Embryos 
correspond to the offspring of an outcross between putative carriers of the pdx1 
mutant allele with wt animals. Sizes for wt and pdx1 mutant allele upon digestion 
with DraI are presented on the right side of the gel. Symbol "wt" refers to genotyping 
negative control performed with DNA from wt embryos, while “L” represents the 1 
kb ladder. (B) Representation of sequencing of genomic DNA obtained from 
zebrafish wt animals (pdx1+/+) and pdx1 homozygous mutants (pdx1-/-). Zebrafish 
pdx1 mutants hold a restriction site for DraI enzyme in that locus. 
Electrophoresis gel of PCR amplification of Tol2 cassette from pCR8GW-iTol2 
plasmid. Symbol "-" refers to PCR negative control (blank), while “L” represents the 
1 kb ladder. PCR amplification was performed testing two alternative annealing 
temperatures, 58 and 60 °C. The amplified cassette name is indicated on the top of 
the gel, while its correspondent size (Tol2 cassette flanked by 50 bp homology arms) 
is depicted at the b ttom.  
A 
B 
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Three concentrations of PDX1 BAC were injected, namely 50, 150 and 500 ng/uL 
of DNA, each one tested with and without co-microinjection of Tol2 mRNA at 25 ng/uL 
[106]. Upon microinjection, the rate of mortality was examined at 10 dpf (Table 8). The 
highest mortality rate was found to be correlated with the highest amount of BAC DNA 
microinjected. Whereas 500 ng appears indeed to be too toxic, a clear difference 
between 50 and 150 ng was not observed, suggesting this as optimal range. 
Table 8. Experimental conditions of PDX1 BAC microinjection in one-cell zebrafish embryos and 
mortality rates. Concentrations of BAC DNA as well as Tol2 mRNA are indicated.  
PDX1 BAC DNA (ng/uL) Tol2 mRNA (ng/uL) Mortality at 10 dpf (%) 
50 
- 30 
25 30 
150 
- 20 
25 10-50 
500 
- 80 
25 90 
 
(7) Genotyping BAC transgenics 
In order to assess transgenesis efficiency values, we employed a genotyping 
strategy to identify BAC transgenic animals. In this experiment, we used batches of four 
zebrafish animals microinjected with the PDX1 BAC to extract DNA, grouped according 
to each condition tested in microinjection. The larvae were collected at 10 dpf to avoid 
contamination from non-integrated DNA fragments. We used primers designed 
specifically to the promoter of the human PDX1 locus (PDX1 P), thus determining 
whether integration of the human transposon into the zebrafish genome occurred. 
 We first tested the specificity of our primers within mixes of human DNA, both from 
PDX1 BAC and gDNA, and zebrafish DNA (ZF) (Figure 31). Using BAC DNA as template 
for PCR amplification, a higher yield of PCR product was obtained comparing to gDNA. 
This difference seems to reflect the presence of a higher number of copies of the 
template in the BAC DNA, when using the same total amount of BAC DNA and gDNA. 
Analysis of PCR products allows to conclude that mixing of zebrafish DNA with human 
DNA sustains primer specificity, since PCR amplification from that DNA mix does not 
show additional PCR products.  
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After confirming primers specificity, we investigated which amount of human DNA 
that could be used in PCR in order to detect a successful integration of the BAC in the 
zebrafish genome. To evaluate PCR sensibility, we estimated the amount of BAC DNA 
or human gDNA employed in PCR that should mimic the event of a single molecule 
insertion of the human PDX1 BAC into the zebrafish genome. Taking into consideration 
the full size of the zebrafish genome and the size of the PDX1 BAC, we estimated that 
the ratio between total amount of BAC DNA and ZF DNA is around 1:104 (see Materials 
and Methods, chapter 9. c) (3)). In other words, when performing a PCR reaction with 10 
ng (10000 pg) of ZF DNA, 1 pg of PDX1 BAC in that reaction should represent 1 copy of 
the BAC integrated in the zebrafish genome. We performed the previous PCR reaction 
using as template the DNA extracted from batches of four zebrafish animals at 10 dpf 
microinjected with the PDX1 BAC. As PCR controls, we used human gDNA, ZF DNA 
and ZF DNA mixed with either human gDNA or the BAC (mimicking 1 copy of BAC per 
1, 100 or 1000 copies of the zebrafish genome, respectively). A first PCR reaction was 
performed with thirty-five amplification cycles, which results were able to detect the 
human PDX1 BAC only in “1 BAC + ZF” (Figure 32 A; see Materials and Methods, 
chapter 9. c) (3)). This indicates that the resolution of the genotyping PCR was sufficient 
to detect one molecule of PDX1 BAC per zebrafish genome. 
Thus, to enhance the sensibility of the PCR even further (Figure 32 B, lane “1 BAC 
+ 100 ZF”), the PCR was performed by increasing the number of amplification cycles to 
Figure 31. Electrophoresis gel of PCR amplification of human PDX1 promoter region (PDX1 P). DNA 
templates used are depicted above the gel, which were the following: PDX1 BAC DNA (BAC), human gDNA 
(gDNA), zebrafish DNA (ZF) mixed with BAC and ZF DNA mixed with human gDNA. ZF DNA corresponds 
to approximately 10 ng. Each template of human DNA was tested in two concentrations: 1 ng and 1 pg for 
BAC DNA and 1 pg and 1 fg for gDNA. Symbol "-" refers to PCR negative control (blank); while “L” represents 
the 1 kb ladder. Size of the amplified region is depicted at the bottom. 
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forty. By this optimization, in both controls, “1 BAC + 1 ZF” and “1 BAC + 100 ZF”, the 
amplification of the human PDX1 BAC was detected, indicating that the resolution 
achieved ranges between one and one hundredth BAC copy per genome. With these 
conditions, the desired amplicon was detected in two distinct batches of injected embryos 
- the two correct bands are identified by the yellow arrows (Figure 32 B, lanes “BAC 50 
ng .4” and “BAC 150 ng .3”). Concomitantly, various unspecific PCR amplicons arose, 
which is expected with such high number of cycles. The two positive batches for the PCR 
derived from embryos microinjected with 50 ng of BAC and 150 ng of BAC, confirming 
that both experimental conditions might be successful. Further optimization of the PCR 
protocol, as well as confirmation by Sanger sequencing of the expected size bands will 
be performed in the near future. As preliminary data, our results suggest that 
microinjection of 50 ng of BAC is sufficient to allow transgenesis, since we were able to 
amplify the correct sequence from the DNA from batches of embryos injected with this 
amount of BAC (Figure 32 B, lane “BAC 50 ng .4”). 
Determination of significant values of transgenesis efficiency is crucial to determine 
the use of the BAC injected animals as founders of a stable transgenic line. To establish 
the PDX1 transgenic line, we planned to inject with the highest amount of BAC DNA 
(150ng) in order to maximize the transgenesis efficiency, since the toxicity range is 
similar. 
The generation of the PDX1 transgenic line will be used to dissect PDX1 
transcriptional regulation and represent a humanized model, which is easy to edit 
genetically, thus allowing deleting CRE to investigate their biological impact on PDX1 
expression. 
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Figure 32. Electrophoresis gels of PCR of the human PDX1 locus from zebrafish animals 
microinjected with the PDX1 BAC. PCR amplification was performed using batches of four zebrafish 
individuals at 10dpf (identified with numbers between 1 and 5) from the three BAC concentrations, along 
with Tol2 mRNA tested in microinjection, or with BAC DNA only (without Tol2), named "CTRL BAC 
500ng". PCR controls (left side of both gels) were performed through amplification of: human gDNA alone 
(gDNA); zebrafish DNA alone (ZF); a mixture of ZF with human gDNA (ZF+gDNA); and mixtures of ZF with 
the BAC in different concentrations, identified at the top of the gel (corresponding to 1 BAC copy in 1, 100 
and 1000 molecules of the zebrafish genome, respectively). Symbol "-" refers to PCR negative control 
(blank), while “L” represents the 1 kb ladder. (A) PCR results obtained with 35 cycles of amplification. (B) 
PCR results obtained with 40 cycles of amplification. 
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General conclusions and future perspectives 
Complex diseases, such as T2D, have been increasing their incidence in worldwide 
human populations. Particularly, more than 422 million adults have been reported as 
diabetic patients in 2016 [68]. As a multifactorial disease, the pathogenesis of diabetes 
outcomes from risk factors including genetic predisposition, aging and environmental 
factors [65-67]. Moreover, similarly to cancer, diabetes diagnosis can be accompanied 
by failure in different organ systems, for instance the central nervous system [121]. 
GWAS have been successfully employed to characterise genetic variants associated to 
disease, which detected several human polymorphisms associated to T2D 
predisposition [122]. T2D-associated polymorphisms are frequently located within non-
coding regions characterised by epigenetic marks of CREs, namely enhancers; 
furthermore, analysis of eQTLs allowed to assign an impact of several of those 
polymorphisms in gene expression dysregulation [7, 123]. Co-localization of T2D-
associated polymorphisms and gene regulatory elements, such as enhancers, suggests 
an impact on transcriptional regulation [34-36]. 
The main focus of this thesis was to explore the regulatory landscape of PDX1, a 
master regulator of pancreatic development and function. Starting from the choice of 
PDX1 as our locus of interest, we analysed the genomic context of a T2D-associated 
SNP identified by GWAS, which is contained within the gene locus. Based on reports 
showing the localization of T2D-associated SNP in genomic regions enriched in 
epigenetic marks used to define enhancers, we defined a putative enhancer sequence 
containing the mentioned polymorphism. Together with other two putative enhancers 
that were defined using chromatin accessibility and conformation data from human 
pancreatic islets, we tested the ability of those sequences to enhance the expression of 
reporter genes in the endocrine pancreas and pancreatic progenitors through zebrafish 
transgenesis. Moreover, we also defined putative insulator sequences flanking PDX1 
regulatory landscape, based on chromatin interactions detected by Hi-C data in human 
pancreatic islets. On one hand, our results showed that the enhancer eSNP, the 
sequence overlapping with the T2D-associated SNP, is able to drive GFP expression in 
the pancreatic domain of zebrafish embryos, although very mildly, while en1 and en2 
sequences were not, therefore they are unable to function as enhancers, at least in this 
reporter assay. On the other hand, our results showed that all the three putative CREs 
successfully function as insulators in an in vivo enhancer blocking assay in zebrafish. 
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Overall, with these results, we were able to map and validate new CREs in the regulatory 
landscape of PDX1.  
Besides screening for CREs contained within PDX1 locus through zebrafish 
transgenesis assays, the novelty of the project presented in this thesis relies on the study 
the full regulatory landscape of this master regulator of the pancreas. While the 
transgenesis assays to validate CREs were performed by isolating the genomic 
sequence and exploring its impact on the expression of a reporter gene, we will further 
study PDX1 CREs without disturbing their original genomic context. For this purpose, a 
PDX1 BAC was selected and evaluated as a reliable representation of the human PDX1 
locus. To introduce the full human PDX1 locus in the zebrafish genome, we took 
advantage of the established protocol of BAC recombineering, by which we inserted a 
Tol2 cassette in the PDX1 BAC, thus improving transgenesis efficiency upon 
microinjection in zebrafish. While the PDX1 BAC was engineered for efficient 
transgenesis, a zebrafish mutant line for the pdx1 locus was reared in the animal facility. 
Zebrafish pdx1 mutants provide an in vivo tool that will further be used to test the ability 
of PDX1 BAC to rescue loss-of-function of the zebrafish ortholog upon transgenesis. 
Preliminary data of PDX1-BAC-Tol2 injection in pdx1 heterozygotes, as well as in wt 
zebrafish, showed a transgenesis efficiency between 5 and 20%. Injected fish are 
growing, and when reached the sexual maturity, they will be screened for germline 
transmission to identify founders for establishing the PDX1-zebrafish line. 
As future perspectives, we aim to develop a transgenic line of animals containing 
PDX1 locus. While maintaining the original structure of its regulatory landscape, we can 
study human cis-regulation of PDX1 in vivo. We aim to assess the impact of the SNP 
mapped in PDX1 regulatory elements previously associated to T2D, as a potential cause 
for the disruption of normal pancreatic function. This will be done using CRISPR-Cas9 
site directed mutagenesis system. In addition, we want to identify novel polymorphisms 
that could potentially impair proper development of the pancreas. Using zebrafish as 
model organism, PDX1 BAC transgenics will constitute an in vivo “tool” that could be 
used to approach both single and congregated impact of non-coding polymorphisms on 
diabetes predisposition.  
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Supplementary Data 
Supplementary Table 1. List of 126 candidate SNPs potentially associated to the development 
of diabetes. The list enumerates: Fasting glycemia- and T2D-associated SNPs retrieved from GWAS 
datasets; genes located nearby those SNPs; chromosomic localization, gene coding sequences (CDS) start 
and end coordinates (GRCh37/hg19), length of CDS and bibliographic references for each SNP. 
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